Dactolisib (BEZ235)

For research use only. Not for use in humans.

目录号：S1009 别名： NVP-BEZ235

Molecular Weight(MW): 469.55

Dactolisib (BEZ235, NVP-BEZ235) 是一种双重ATP竞争性 PI3K 和 mTOR 抑制剂，在无细胞试验中，抑制 p110α/γ/δ/β 和 mTOR(p70S6K) 的 IC50 分别为 4 nM /5 nM /7 nM /75 nM /6 nM。在 3T3^TopBP1-ER 细胞中抑制 ATR，IC50 为 21 nM，而对 Akt 和 PDK1 的抑制作用很弱。Dactolisib可诱导自噬并抑制HIV-1的复制。Phase 2。

规格

价格

库存

购买数量

50mg	RMB 895.88	现货
100mg	RMB 1414.41	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Dactolisib (BEZ235)发表文献286篇：

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2018, 560(7718):372-376

PubMed: 30046109 ( click the link to review the publication )

Nature, 2017, 543(7647):728-732

PubMed: 28321130 ( click the link to review the publication )

Cancer Cell, 2017, 31(3):424-435

PubMed: 28292440 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Nature, 2014, 30;514(7524):628-32.

PubMed: 25119024 ( click the link to review the publication )

Nature, 2012, 26;487(7408):505-9.

PubMed: 22763448 ( click the link to review the publication )

Cell, 2012, 13;149(2):307-21.

PubMed: 22500798 ( click the link to review the publication )

Cancer Cell, 2012, 21(2):155-67

PubMed: 22340590 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1825

PubMed: 32286280 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Biomaterials, 2020, 246:120012

PubMed: 32276198 ( click the link to review the publication )

Theranostics, 2020, 16;10(14):6448-6466

PubMed: 32483463 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-1255-y

PubMed: 32157217 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32085396 ( click the link to review the publication )

Cell Death Dis, 2020, 29;11(5):406

PubMed: 32471991 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):479-489

PubMed: 31672764 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.1131.2019

PubMed: 32371585 ( click the link to review the publication )

J Cancer, 2020, 11(9):2552-2559

PubMed: 32201525 ( click the link to review the publication )

Front Cell Neurosci, 2020, 15;14:134

PubMed: 32477073 ( click the link to review the publication )

Int J Mol Sci, 2020, 18;21(8):2825

PubMed: 32325639 ( click the link to review the publication )

Sci Rep, 2020, 10(1):218

PubMed: 31937834 ( click the link to review the publication )
BMC Cancer, 2020, 20(1):4

PubMed: 31898540 ( click the link to review the publication )

G3 (Bethesda), 2020, 4;10(5):1585-1597

PubMed: 32265286 ( click the link to review the publication )

Mol Biol Rep, 2020, 47(3):2217-2230

PubMed: 32088816 ( click the link to review the publication )

J BUON, 2020, 020;25(1):464-471

PubMed: 32277670 ( click the link to review the publication )

Nanoscale Res Lett, 2020, 15(1):63

PubMed: 32219609 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

bioRxiv, 2020, 2020/9/20.4.7.30734

PubMed: 32511305 ( click the link to review the publication )

Biomaterials, 2020, 230:119618

PubMed: 31757530 ( click the link to review the publication )

Clin Transl Med, 2020, 9(1):22

PubMed: 32112175 ( click the link to review the publication )

Gastroenterology, 2019, 10.1053/j.gastro.2019.11.013

PubMed: 31734182 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Cancer Res, 2019, 79(1):209-219

PubMed: 30389701 ( click the link to review the publication )

Cell Rep, 2019, 27(3):820-834

PubMed: 30995479 ( click the link to review the publication )

Cell Rep, 2019, 26(3):608-623

PubMed: 30650355 ( click the link to review the publication )

Cell Death Differ, 2019, 26(9):1670-1687

PubMed: 30683918 ( click the link to review the publication )

Radiology, 2019, 10.1148/radiol.2019190115

PubMed: 31335281 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Pathol, 2019, 10.1002/path.5277

PubMed: 30957234 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):481

PubMed: 31801598 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4063-4078

PubMed: 30952635 ( click the link to review the publication )

Cancers, 2019, 11(2)

PubMed: 30813295 ( click the link to review the publication )

Cancers, 2019, 11(5)

PubMed: 31121848 ( click the link to review the publication )

Biomacromolecules, 2019, 20(9):3313-3323

PubMed: 31198025 ( click the link to review the publication )
J Dent Res, 2019, 98(3):304-312

PubMed: 30513244 ( click the link to review the publication )

Mol Cancer Ther, 2019, 10.1158/1535-7163

PubMed: 31289138 ( click the link to review the publication )

Front Oncol, 2019, 9:463

PubMed: 31214505 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Cancer, 2019, 10(5):1197-1208

PubMed: 30854129 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(1):145-159

PubMed: 30755818 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:336

PubMed: 31871431 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18249-18261

PubMed: 30851074 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:7933-7951

PubMed: 31686909 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2019, 60(7):2764-2772

PubMed: 31247083 ( click the link to review the publication )

BMC Cancer, 2019, 20(1):1

PubMed: 31892356 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):404-416

PubMed: 30550927 ( click the link to review the publication )

Am J Transl Res, 2019, 11(1):87-105

PubMed: 30787971 ( click the link to review the publication )

Int J Mol Med, 2019, 43(1):47-56

PubMed: 30387804 ( click the link to review the publication )

Vet Comp Oncol, 2019, 10.1111/vco.12490

PubMed: 31069942 ( click the link to review the publication )

Pharm Biol, 2019, 57(1):412-423

PubMed: 31230505 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3745-3755

PubMed: 31262901 ( click the link to review the publication )

Ren Fail, 2019, 41(1):267-277

PubMed: 30982374 ( click the link to review the publication )

Assay Drug Dev Technol, 2019, 17(3):140-149

PubMed: 30958703 ( click the link to review the publication )

Nagoya J Med Sci, 2019, 81(1):93-102

PubMed: 30962658 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Viruses, 2019, 11(3)

PubMed: 30875748 ( click the link to review the publication )
Mol Ther Nucleic Acids, 2019, 14:287-300

PubMed: 30654190 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(20):5165-5177

PubMed: 29941485 ( click the link to review the publication )

Cancer Res, 2018, 78(9):2383-2395

PubMed: 29440171 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cancer Res, 2018, 78(15):4396-4410

PubMed: 29844118 ( click the link to review the publication )

Radiology, 2018, 288(3):730-738

PubMed: 29737948 ( click the link to review the publication )

J Invest Dermatol, 2018, 138(11):2377-2387

PubMed: 29758280 ( click the link to review the publication )

J Pathol, 2018, 245(1):101-113

PubMed: 29443392 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563275 ( click the link to review the publication )

Cancers, 2018, 10(2)

PubMed: 29370086 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):123

PubMed: 29374144 ( click the link to review the publication )

Cell Death Dis, 2018, 9(2):45

PubMed: 29352118 ( click the link to review the publication )

J Cancer, 2018, 9(6):987-997

PubMed: 29581778 ( click the link to review the publication )

Glia, 2018, 66(5):999-1015

PubMed: 29392777 ( click the link to review the publication )

Exp Mol Med, 2018, 50(3):e463

PubMed: 29869624 ( click the link to review the publication )

Radiat Oncol, 2018, 13(1):76

PubMed: 29685176 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):347-354

PubMed: 28958992 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):599-609

PubMed: 29330285 ( click the link to review the publication )

Front Oncol, 2018, 8:249

PubMed: 30013951 ( click the link to review the publication )

Antiviral Res, 2018, 153:39-48

PubMed: 29425831 ( click the link to review the publication )

Biochem Pharmacol, 2018, 10.1016/j.bcp.2018.10.011

PubMed: 30342021 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 40(2):268-278

PubMed: 29777202 ( click the link to review the publication )
Invest New Drugs, 2018, 10.1007/s10637-018-0698-2

PubMed: 30456603 ( click the link to review the publication )

Int J Hyperthermia, 2018, 34(6):812-823

PubMed: 28954551 ( click the link to review the publication )

Cancer Med, 2018, 7(9):4744-4754

PubMed: 30109783 ( click the link to review the publication )

Am J Transl Res, 2018, 10(12):4376-4384

PubMed: 30662679 ( click the link to review the publication )

Oncol Rep, 2018, 39(2):711-720

PubMed: 29207150 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2353-2362

PubMed: 30066933 ( click the link to review the publication )

Oncol Rep, 2018, 39(4):1731-1738

PubMed: 29393465 ( click the link to review the publication )

J Cell Biochem, 2018, 119(3):2708-2718

PubMed: 29057547 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2461-2472

PubMed: 29436587 ( click the link to review the publication )

Int J Mol Med, 2018, 41(5):2755-2763

PubMed: 29436606 ( click the link to review the publication )

PLoS One, 2018, 13(1):e0190854

PubMed: 29357370 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 507(1-4):311-318

PubMed: 30466782 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(2):2004-2009

PubMed: 29253572 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 504(4):721-726

PubMed: 30217442 ( click the link to review the publication )

Anticancer Res, 2018, 38(3):1407-1414

PubMed: 29491065 ( click the link to review the publication )

Pathol Res Pract, 2018, 214(6):889-895

PubMed: 29653746 ( click the link to review the publication )

Oncol Lett, 2018, 15(6):9655-9662

PubMed: 29928341 ( click the link to review the publication )

Oncotarget, 2018, 9(6):7023-7035

PubMed: 29467947 ( click the link to review the publication )

Sci Rep, 2018, 8(1):1652

PubMed: 29374181 ( click the link to review the publication )

Discov Med, 2018, 25(140):265-275

PubMed: 30021100 ( click the link to review the publication )

Mol Cell, 2017, 65(6):999-1013

PubMed: 28306514 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1636

PubMed: 29158506 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1278

PubMed: 29097657 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1274-1285

PubMed: 28232476 ( click the link to review the publication )
Clin Cancer Res, 2017, 23(12):3045-3052

PubMed: 28007777 ( click the link to review the publication )

Leukemia, 2017, 31(4):922-933

PubMed: 27686868 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(7):E1072-E1080

PubMed: 28137841 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(5):1286-1298

PubMed: 27553832 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):9

PubMed: 28061880 ( click the link to review the publication )

Cancer Lett, 2017, 388:12-20

PubMed: 27894954 ( click the link to review the publication )

Cancer Lett, 2017, 406:1-11

PubMed: 28774796 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(5):1813-1828

PubMed: 29065414 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(4):729-738

PubMed: 28119490 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(9):1779-1790

PubMed: 28619753 ( click the link to review the publication )

J Nutr Biochem, 2017, 41:124-136

PubMed: 28092744 ( click the link to review the publication )

J Cell Mol Med, 2017, 21(3):467-474

PubMed: 27680680 ( click the link to review the publication )

Mol Imaging Biol, 2017, 19(3):421-428

PubMed: 27770401 ( click the link to review the publication )

Acta Pharmacol Sin, 2017, 38(3):382-391

PubMed: 28042875 ( click the link to review the publication )

Mol Cell Neurosci, 2017, 82:66-75

PubMed: 28461220 ( click the link to review the publication )

Cell Cycle, 2017, 16(24):2386-2395

PubMed: 28980866 ( click the link to review the publication )

World J Gastroenterol, 2017, 23(42):7551-7562

PubMed: 29204055 ( click the link to review the publication )

Drug Des Devel Ther, 2017, 11:1115-1126

PubMed: 28435223 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(1):209-216

PubMed: 28712871 ( click the link to review the publication )

Oncol Lett, 2017, 14(6):7970-7976

PubMed: 29250185 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5077-5087

PubMed: 29118584 ( click the link to review the publication )

Oncotarget, 2017, 8(33):53968-53977

PubMed: 28903316 ( click the link to review the publication )

Oncotarget, 2017, 8(64):107977-107990

PubMed: 29296217 ( click the link to review the publication )

Oncotarget, 2017, 8(7):11937-11949

PubMed: 28060760 ( click the link to review the publication )
Oncotarget, 2017, 8(30):49380-49394

PubMed: 28537902 ( click the link to review the publication )

Oncotarget, 2017, 8(63):106486-106498

PubMed: 29290965 ( click the link to review the publication )

Nano Lett, 2017, 17(11):7160-7168

PubMed: 29035540 ( click the link to review the publication )

Nat Commun, 2016, 7:11971

PubMed: 27321283 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

EMBO J, 2016, 35(20):2192-2212

PubMed: 27625374 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(11):2744-54

PubMed: 26712685 ( click the link to review the publication )

J Exp Clin Cancer Res, 2016, 35:52

PubMed: 27009084 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2016, 29(6):643-655

PubMed: 27463366 ( click the link to review the publication )

Mol Oncol, 2016, 10(1):101-12

PubMed: 26471831 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4490-4504

PubMed: 27794612 ( click the link to review the publication )

Mol Carcinog, 2016, 55(12):2135-2155

PubMed: 26764221 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):285-93

PubMed: 27176231 ( click the link to review the publication )

Biomed Pharmacother, 2016, 77:161-6

PubMed: 26796280 ( click the link to review the publication )

BMC Cancer, 2016, 16:657

PubMed: 27542970 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 79:393-400

PubMed: 27620077 ( click the link to review the publication )

Cancer Med, 2016, 5(10):2953-2964

PubMed: 27539383 ( click the link to review the publication )

Transl Oncol, 2016, 9(3):197-202

PubMed: 27267837 ( click the link to review the publication )

Cell Biochem Funct, 2016, 34(2):69-81

PubMed: 26919061 ( click the link to review the publication )

Animal, 2016, 10(8):1319-27

PubMed: 26956906 ( click the link to review the publication )

Anticancer Res, 2016, 36(4):1673-82

PubMed: 27069145 ( click the link to review the publication )

Target Oncol, 2016, 11(2):209-27

PubMed: 26453055 ( click the link to review the publication )

Oncotarget, 2016, 7(44):71211-71222

PubMed: 27655717 ( click the link to review the publication )
Tumour Biol, 2016, 37(1):419-24

PubMed: 26219899 ( click the link to review the publication )

Heliyon, 2016, 2(11):e00194

PubMed: 27896318 ( click the link to review the publication )

Oncotarget, 2016, 8(32):52193-52210

PubMed: 28881723 ( click the link to review the publication )

Oncotarget, 2016, 7(40):65147-65156

PubMed: 27556501 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3947-65

PubMed: 26678033 ( click the link to review the publication )

Oncotarget, 2016, 7(12):13797-809

PubMed: 26883194 ( click the link to review the publication )

J Clin Invest, 2015, 125(3):1174-88

PubMed: 25664849 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(24):5499-5510

PubMed: 26272063 ( click the link to review the publication )

Leukemia, 2015, 29(4):828-38

PubMed: 25322685 ( click the link to review the publication )

Cancer Res, 2015, 75(24):5318-28

PubMed: 26670562 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2014.444

PubMed: 25619831 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.143

PubMed: 25961924 ( click the link to review the publication )

EBioMedicine, 2015, 2(12):1944-56

PubMed: 26844273 ( click the link to review the publication )

Cancer Lett, 2015, 367(1):58-68

PubMed: 26188279 ( click the link to review the publication )

Cancer Lett, 2015, 359(1):47-56

PubMed: ( click the link to review the publication )

Breast Cancer Res, 2015, 17:32

PubMed: 25849721 ( click the link to review the publication )

J Neurosci, 2015, 35(9):3893-902

PubMed: 25740518 ( click the link to review the publication )

Cancer Discov, 2015, 5(12):1262-70

PubMed: 26370156 ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(4):1014-23

PubMed: 25673820 ( click the link to review the publication )

Neoplasia, 2015, 17(1):16-31

PubMed: 25622896 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:65

PubMed: 26130968 ( click the link to review the publication )

J Dermatol Sci, 2015, 78(1):44-50

PubMed: 25726712 ( click the link to review the publication )

Mol Imaging Biol, 2015, 17(3):403-12

PubMed: 25465391 ( click the link to review the publication )
Cancer Biol Ther, 2015, 16(4):580-8

PubMed: 25793663 ( click the link to review the publication )

Prostate, 2015, 75(15):1747-59

PubMed: 26250606 ( click the link to review the publication )

BMC Cancer, 2015, 15:894

PubMed: 26560145 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

PLoS One, 2015, 10(12):e0144708

PubMed: 26678268 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123410

PubMed: 25844720 ( click the link to review the publication )

Onco Targets Ther, 2015, 8:269-77

PubMed: 25674002 ( click the link to review the publication )

Biomed Res Int, 2015, 2015:870918

PubMed: 26557706 ( click the link to review the publication )

ACS Chem Biol, 2015, 10(10):2193-8

PubMed: 26270491 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )

Oncotarget, 2015, 6(18):15814-27

PubMed: 26158412 ( click the link to review the publication )

Oncotarget, 2015, 6(32):32930-43

PubMed: 26431379 ( click the link to review the publication )

EJNMMI Res, 2015, 5(1):61

PubMed: 26543028 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Nano Lett, 2015, 15(12):8032-43

PubMed: 26540670 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(2):404-12

PubMed: 24192926 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(8):2126-35

PubMed: 24573549 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(5):1235-48

PubMed: 24366691 ( click the link to review the publication )

Cancer Res, 2014, 74(10):2846-56

PubMed: 24614082 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.12.034

PubMed: 25554016 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 10.1111/pcmr.12268

PubMed: 24890688 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )
Cell Death Dis, 2014, 5:e1434

PubMed: 25275595 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1013

PubMed: 24457957 ( click the link to review the publication )

FASEB J, 2014, fj.13-247924

PubMed: 24903273 ( click the link to review the publication )

Mol Oncol, 2014, 8(3):544-54

PubMed: 24476679 ( click the link to review the publication )

J Virol, 2014, 88(9):5152-64

PubMed: 24574393 ( click the link to review the publication )

Magnet Reson Med, 2014, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

Apoptosis, 2014, 19(5):895-904

PubMed: 24652480 ( click the link to review the publication )

Endocrinology, 2014, 155(4):1510-9

PubMed: 24476133 ( click the link to review the publication )

Expert Opin Inv Drugs, 2014, 23(4):469-87

PubMed: 24490883 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(13):2517-32

PubMed: 24777602 ( click the link to review the publication )

Invest New Drugs, 2014, 32(6):1134-43

PubMed: 25152245 ( click the link to review the publication )

Anal Bioanal Chem, 2014, 406(15):3743-54

PubMed: 24817345 ( click the link to review the publication )

BMC Cancer, 2014, 14:283

PubMed: 24758408 ( click the link to review the publication )

Eur J Pharmacol, 2014, 741:195-204

PubMed: 25160744 ( click the link to review the publication )

Drug Des Devel Ther, 2014, 8:255-62

PubMed: 24600206 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(8):e105280

PubMed: 25144531 ( click the link to review the publication )

PLoS One, 2014, 9(9):e108193

PubMed: 25247710 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 455(3-4):256-61

PubMed: 25449280 ( click the link to review the publication )

Biochem Biophy Res Co, 2014, 10.1016/j.bbrc.2014.11.002

PubMed: ( click the link to review the publication )

Cardiovasc Inter Rad, 2014, 37(5):1343-51

PubMed: 24452318 ( click the link to review the publication )

Eur Biophys J, 2014, 9(4):e95243

PubMed: 24743578 ( click the link to review the publication )
Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(11):708-14

PubMed: 24013279 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Cancer Res, 2013, 73(11):3402-11

PubMed: 23585456 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Int J Cancer, 2013, 133(9):2089-101

PubMed: 23629727 ( click the link to review the publication )

Oncogene, 2013, 32(17):2179-88

PubMed: 22689062 ( click the link to review the publication )

Cancer Lett, 2013, 329(2):236-42

PubMed: 23200669 ( click the link to review the publication )

Sci Signal, 2013, 6(271):ra25

PubMed: 23592840 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(1):R16

PubMed: 23448424 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2013, 26(4):518-26

PubMed: 23582185 ( click the link to review the publication )

Exp Mol Med, 2013, 45:e64

PubMed: 24263233 ( click the link to review the publication )

J Mater Chem B, 2013, 5602-5610

PubMed: ( click the link to review the publication )

Cancer Sci, 2013, 104(7):896-903

PubMed: 23578175 ( click the link to review the publication )

Mol Cancer Res, 2013, 11(10):1269-78

PubMed: 23814023 ( click the link to review the publication )

Magn Reson Med, 2013, 71(6):1973-81

PubMed: 23878023 ( click the link to review the publication )

J Biol Chem, 2013, 288(42):30387-98

PubMed: 24014036 ( click the link to review the publication )

Acta Pharmacol Sin, 2013, 34(5):681-90

PubMed: 23603977 ( click the link to review the publication )

Transl Oncol, 2013, 6(5):586-95

PubMed: 24151539 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1297-307

PubMed: 23479136 ( click the link to review the publication )

PLoS One, 2013, 8(3):e59879

PubMed: 23533654 ( click the link to review the publication )

J Biomol Screen, 2013, 19(1):131-44

PubMed: 23954931 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2515-25

PubMed: 22392911 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Oncogene, 2012, 33(2):236-45

PubMed: 23246970 ( click the link to review the publication )

J Invest Dermatol, 2012, 132(7):1850-9

PubMed: 22437314 ( click the link to review the publication )

Sci Signal, 2012, 5(224):rs4

PubMed: 22589389 ( click the link to review the publication )

J Neurosci, 2012, 32(1):264-74

PubMed: 22219288 ( click the link to review the publication )

Neoplasia, 2012, 14(1):34-43

PubMed: 22355272 ( click the link to review the publication )

Cancer Sci, 2012, 103(11):1955-60

PubMed: 22925034 ( click the link to review the publication )

J Virol, 2012, 86(8):4578-85

PubMed: 22345463 ( click the link to review the publication )

Mol Pharmacol, 2012, 81(5):748-58

PubMed: 22357666 ( click the link to review the publication )

Hum Pathol, 2012, 43(12):2197-206

PubMed: 22705003 ( click the link to review the publication )

J Surg Oncol, 2012, 106(8):972-80

PubMed: 22711648 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Blood, 2011, 118(14):3911-21

PubMed: 21821710 ( click the link to review the publication )

Cancer Res, 2011, 71(15):5067-74

PubMed: 21803746 ( click the link to review the publication )

Breast Cancer Res, 2011, 13(3):R52

PubMed: 21595894 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Clin Cancer Res, 2010, 16(24):6029-39

PubMed: 21169255 ( click the link to review the publication )

Cancer Res, 2010, 70(11):4709-18

PubMed: 20484037 ( click the link to review the publication )

Cancer Res, 2010, 70(12):4982-94

PubMed: 20530683 ( click the link to review the publication )

Eur J Cancer, 2010, 46(6):1111-21

PubMed: 20129775 ( click the link to review the publication )

Biochemistry, 2010, 49(39):8488-98

PubMed: 20804212 ( click the link to review the publication )

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述

靶点

p110α ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR (p70S6K) ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	ATR ^[8] (3T3^TopBP1-ER cells)	点击更多
4 nM	5 nM	6 nM	7 nM	21 nM	点击更多

体外研究

BEZ235显著降低mTOR活化的激酶p70S6K的磷酸化水平。BEZ235导致S235/S236P-RPS6水平减少，IC50为6.5 nM。BEZ235抗mTOR的活性使用生化mTOR K-LISA试验测定，IC50为20.7 nM。BEZ235对其β旁系同源物的活性稍弱，IC50为75 nM。在人肿瘤细胞中，PI3K/Akt/mTOR通路经常被组成性活化。BEZ235阻断PI3K和mTOR激酶活性，通过结合于这些酶的ATP结合槽发挥作用。用逐渐增加浓度BEZ235处理PTEN-null细胞系PC3M和U87MG时，导致细胞增殖剂量依赖性减少，平均GI50为10-12 nM。^[1] BEZ235是一种mTORC1/2催化抑制剂。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Trypanosoma brucei brucei	MkjBRY51cW2rY4LvZolidCCDc4PhfS=>		MV[xPEBp	MX3EUXNQ	M4X4NmFvfGm2conwZY5we2:vYXygZYN1cX[rdImge4l1cCCHQ{WwJI9nKDBwMECyOUDPxE1?	NHTkN\|kzPDhyNUm0Oi=>
MCF7	NVOxbXBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvBNE4xOS1zMECg{txO	NVGxSnJsPDhiaB?=	MWnEUXNQ	NFHIR\|dKSzVyPUCuO\|Mh\|ryP	NFjDNGMzOzh5MUmwOC=>
HCT116	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjNNm4xOC5yMT2xNFAh\|ryP	Mlf5OFghcA>?	MkXBSG1UVw>?	MX7JR\|UxRTFwMU[g{txO	M2XUe\|I{QDdzOUC0
U87MG	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLUNoNZOC5yMT2xNFAh\|ryP	MYW0PEBp	NXzo[4ZWTE2VTx?=	M2LGVGlEPTB;MT6zNkDPxE1?	MVKyN\|g4OTlyNB?=
HBC4	M2C2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWCwMlAyNTFyMDFOwG0>	NYLCeGNJPDhiaB?=		M4LSOWxw\yCJSUWwQU05NjZzIF2=	NFjMdnozOjN\|NkK0Oi=>
BSY1	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEO3U3UxNjBzLUGwNEDPxE1?	MofVOFghcA>?		MX\Mc4chT0l3ME2tPE41QCCP	Ml3UNlI{OzZ{NE[=
HBC5	M1TDN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOwMlAyNTFyMDFOwG0>	MVu0PEBp		MlPXUI9oKEeLNUC9MVcvQDdiTR?=	M4DRSVIzOzN4MkS2
MCF7	NYe0NVZ1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWSwMlAyNTFyMDFOwG0>	MVS0PEBp		MkfKUI9oKEeLNUC9MVgvOTZiTR?=	NYL0ZnI{OjJ\|M{[yOFY>
MDA-MB-231	MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\IelAvODFvMUCwJO69VQ>?	NF71[pI1QCCq		NGS2NJNNd2diR1m1NF0uQC5yOTDN	NInydoEzOjN\|NkK0Oi=>
U251	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnDepZmOC5yMT2xNFAh\|ryP	M{C5SVQ5KGh?		NEHFPGFNd2diR1m1NF0uPy54NjDN	MXWyNlM{PjJ2Nh?=
SF268	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmwMlAyNTFyMDFOwG0>	NV7DTXdLPDhiaB?=		M2K3VWxw\yCJSUWwQU04Njl{IF2=	NUW0NVJ5OjJ\|M{[yOFY>
SF295	NEXHXWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4DwblAvODFvMUCwJO69VQ>?	M4nhOFQ5KGh?		NHvQUI9Nd2diR1m1NF0uQC5\|MTDN	M1vvZ\|IzOzN4MkS2
SF539	NXq4NYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PVflAvODFvMUCwJO69VQ>?	M1\DNFQ5KGh?		MXXMc4chT0l3ME2tPE42QSCP	NV76c4JzOjJ\|M{[yOFY>
SNB75	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrxRVJCOC5yMT2xNFAh\|ryP	NF[4ZlM1QCCq		NX22V4dwVG:pIFfJOVA:NThwNUigUS=>	MXSyNlM{PjJ2Nh?=
SNB78	NGHzNZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY[wMlAyNTFyMDFOwG0>	MnvqOFghcA>?		NGPuS3dNd2diR1m1NF0uQC54NTDN	NXnlVIR2OjJ\|M{[yOFY>
HCC2998	M3zDXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGwMlAyNTFyMDFOwG0>	MlXvOFghcA>?		MUnMc4chT0l3ME2tPE4xPSCP	M4nZWlIzOzN4MkS2
KM12	MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzBNE4xOS1zMECg{txO	NFH5VIo1QCCq		NW\GU5I3VG:pIFfJOVA:NTdwNUSgUS=>	M1f2WlIzOzN4MkS2
HT-29	NUHHW5BoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPYSZVsOC5yMT2xNFAh\|ryP	M1fneVQ5KGh?		NIXMWGpNd2diR1m1NF0uPy55NTDN	MX6yNlM{PjJ2Nh?=
HCT15	M{fUfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\ONE4xOS1zMECg{txO	MYG0PEBp		MlnUUI9oKEeLNUC9MVgvODNiTR?=	M{O5blIzOzN4MkS2
HCT116	NV:1WFFsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{fXRVAvODFvMUCwJO69VQ>?	MkLVOFghcA>?		Mmi0UI9oKEeLNUC9MVcvPjFiTR?=	M2DrO\|IzOzN4MkS2
NCI-H23	M{O3Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rVRlAvODFvMUCwJO69VQ>?	MnLJOFghcA>?		MkD2UI9oKEeLNUC9MVcvPjRiTR?=	MorhNlI{OzZ{NE[=
NCI-H226	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NY[xTVQ3OC5yMT2xNFAh\|ryP	NX62eZc5PDhiaB?=		MlrKUI9oKEeLNUC9MVgvPDRiTR?=	NEHnUIszOjN\|NkK0Oi=>
NCI-H522	NIL6eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjyVGsxNjBzLUGwNEDPxE1?	MWi0PEBp		NVntflhHVG:pIFfJOVA:NThwNEWgUS=>	M2r2TFIzOzN4MkS2
NCI-H438	NFf5OFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XkVlAvODFvMUCwJO69VQ>?	NXTzVHdTPDhiaB?=		MmXQUI9oKEeLNUC9MVgvOTFiTR?=	M4HkOlIzOzN4MkS2
A549	NYO3doFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknjNE4xOS1zMECg{txO	M4X3TFQ5KGh?		NHfh[nFNd2diR1m1NF0uQC5yNzDN	M3vETFIzOzN4MkS2
DMS273	M3rlUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjFZZAxNjBzLUGwNEDPxE1?	MVS0PEBp		M{\sWGxw\yCJSUWwQU04NjhyIF2=	MY[yNlM{PjJ2Nh?=
DMS114	M1n3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrEUmIxNjBzLUGwNEDPxE1?	MXq0PEBp		M1jDRmxw\yCJSUWwQU05NjN7IF2=	MmPXNlI{OzZ{NE[=
LOXIMVI	M{G2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF32boExNjBzLUGwNEDPxE1?	NEDje3Q1QCCq		MnG1UI9oKEeLNUC9MVgvPjZiTR?=	NIXIb5IzOjN\|NkK0Oi=>
OVCAR3	NHfBRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfjNE4xOS1zMECg{txO	MkG4OFghcA>?		M4HGOWxw\yCJSUWwQU05NjF5IF2=	M1L1XlIzOzN4MkS2
OVCAR4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPYSXM3OC5yMT2xNFAh\|ryP	NGPL[Zc1QCCq		NVnPcIVMVG:pIFfJOVA:NThwNUigUS=>	NX21OJBIOjJ\|M{[yOFY>
OVCAR5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYmwMlAyNTFyMDFOwG0>	Mlm3OFghcA>?		M4f6ZWxw\yCJSUWwQU04NjV5IF2=	M2jOeVIzOzN4MkS2
OVCAR8	Mkf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuwMlAyNTFyMDFOwG0>	MmTyOFghcA>?		M{nmU2xw\yCJSUWwQU04Njh2IF2=	MVOyNlM{PjJ2Nh?=
SKOV3	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLNdlUxNjBzLUGwNEDPxE1?	NUCxNY5jPDhiaB?=		MV\Mc4chT0l3ME2tPE41OSCP	MV:yNlM{PjJ2Nh?=
RXF631L	M1OyZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHuxNJYxNjBzLUGwNEDPxE1?	NF[5c4g1QCCq		M3\Kfmxw\yCJSUWwQU05NjJzIF2=	NH3TfWszOjN\|NkK0Oi=>
ACHN	Mn3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe0UZJ[OC5yMT2xNFAh\|ryP	MV[0PEBp		NVPwXoV2VG:pIFfJOVA:NTdwOUWgUS=>	M3rrdlIzOzN4MkS2
St-4	NXn4WlUyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm3[2kxNjBzLUGwNEDPxE1?	MV[0PEBp		MofuUI9oKEeLNUC9MVcvPDdiTR?=	M1;JfVIzOzN4MkS2
MKN1	M1jwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n4W\|AvODFvMUCwJO69VQ>?	M{C4VlQ5KGh?		MXnMc4chT0l3ME2tPE41OSCP	M1vRNFIzOzN4MkS2
MKN7	NGq4NllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofsNE4xOS1zMECg{txO	NUHOdGUyPDhiaB?=		M3Hx[2xw\yCJSUWwQU04NjZ6IF2=	MXGyNlM{PjJ2Nh?=
MKN28	NYPOb3hDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmS3NE4xOS1zMECg{txO	MVm0PEBp		MWTMc4chT0l3ME2tO{4xPyCP	MnWxNlI{OzZ{NE[=
MKN45	M175[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH\OSYMxNjBzLUGwNEDPxE1?	MnPNOFghcA>?		MWHMc4chT0l3ME2tPE4{PCCP	MV:yNlM{PjJ2Nh?=
MKN74	MnP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITpUokxNjBzLUGwNEDPxE1?	NWH1[lJbPDhiaB?=		M{WweGxw\yCJSUWwQU04NjR{IF2=	Ml7zNlI{OzZ{NE[=
DU145	MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M121XVAvODFvMUCwJO69VQ>?	NWHTN\|R3PDhiaB?=		NH7sUGpNd2diR1m1NF0uQC5zNjDN	MWSyNlM{PjJ2Nh?=
PC3	MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFixUFgxNjBzLUGwNEDPxE1?	NVXhXGpNPDhiaB?=		M37WbGxw\yCJSUWwQU05NjZ4IF2=	Ml7FNlI{OzZ{NE[=
Trypanosoma brucei brucei	MkjVSpVv[3Srb36gRZN{[Xl?	NF;1c5YzODBibl2=	MoHCNVIhcA>?	MnjISG1UVw>?	M1T2XmRm[3KnYYPlJIlvKHCqb4PwbI91cWS7bDDpco9{cXSxbDDwbI9{eGijdHWgcIV3\Wx?	NWi3WHJbOjR6MEW5OFY>
Trypanosoma brucei brucei	MXXGeY5kfGmxbjDBd5NigQ>?		M3XHUVE5KGh?	M2DFVmROW09?	NXnIcodTUW6qaXLpeIlwdiCxZjDy[YNmeHSxcj3t[YRq[XSnZDDlcoRw[3m2b4Ppd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjD0doFve2[ncoLpckB2eHSja3W=	MWCyOFgxPTl2Nh?=
Trypanosoma brucei brucei	MnuwSpVv[3Srb36gRZN{[Xl?	MkDaNlAxKG6P	NFnkflMyOiCq	MXTEUXNQ	NHTleYZG\m[nY4Sgc44he3CqaX7nc416dGWrbjDs[ZZmdA>?	NW\HRXpiOjR6MEW5OFY>
Trypanosoma brucei brucei	MWnGeY5kfGmxbjDBd5NigQ>?	M{fHO\|IxOCCwTR?=	M1P0TVEzKGh?	NHrTWYRFVVOR	NH7ZbZlG\m[nY4Sgc44heGixc4DoZZRq\HmuY3jvcIlv\SCuZY\lcC=>	MmrQNlQ5ODV7NE[=
UM-UC-3	NWOwZoc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUfuOGdSUUN3ME2zNVUheE1?	MUXTRW5ITVJ?
SBC-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULSVIN[UUN3ME23OFIheE1?	MkPTV2FPT0WU
MKN1	NFPTZnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTJwODDuUS=>	NV\HcmF2W0GQR1XS
NCI-H720	M1vrfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDydYpJUUN3ME2zMlU4KG6P	NF\sc5ZUSU6JRWK=
BFTC-909	NEfZdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M33WPGlEPTB;Mz63NUBvVQ>?	NYLWXoRqW0GQR1XS
BPH-1	M{TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHYTWM2OD12Lke2JI5O	M3HX[3NCVkeHUh?=
PC-3	M3jWWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{P5OWlEPTB;NT6wPUBvVQ>?	NWPTN4NEW0GQR1XS
AN3-CA	NX3EUlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTVwNU[gcm0>	MUnTRW5ITVJ?
HN	Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTVwOU[gcm0>	NFLPdHhUSU6JRWK=
HCC2218	MkXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTZwNkGgcm0>	MkHZV2FPT0WU
KP-4	NXK0TGRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX3kWFNwUUN3ME23JI5O	M1LVR3NCVkeHUh?=
LU-139	M4KzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkjWTWM2OD15Lke3JI5O	MXfTRW5ITVJ?
ETK-1	NIfiVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYrpbJhKUUN3ME23Mlg5KG6P	M1HlVXNCVkeHUh?=
Ramos-2G6-4C10	NVrJ[Hk6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRThwNEmgcm0>	MlLYV2FPT0WU
MHH-PREB-1	MoHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFyx[FJKSzVyPUmuNVIhdk1?	M{jCWnNCVkeHUh?=
DU-4475	NG[zdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFG4bXRKSzVyPUmuOFQhdk1?	NUPxRmlrW0GQR1XS
NCI-H1666	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHGb2w5UUN3ME25MlcyKG6P	NFzvRoJUSU6JRWK=
CAMA-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TrUmlEPTB;OT64JI5O	MmDWV2FPT0WU
TYK-nu	M4faXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nj[WlEPTB;OT65OEBvVQ>?	NITNdXJUSU6JRWK=
MFE-280	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TRcmlEPTB;OT65PUBvVQ>?	MkXnV2FPT0WU
A549	NWDtSHpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF64dGhKSzVyPUGwMlE1KG6P	M1nDW3NCVkeHUh?=
769-P	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYTJR\|UxRTFyLkS0JI5O	M2HBfnNCVkeHUh?=
L-363	M2HIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG2XWJKSzVyPUGwMlY6KG6P	MWTTRW5ITVJ?
ES8	NGr4XolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\0bpJKSzVyPUGwMlkhdk1?	NVHnOHlmW0GQR1XS
PA-1	NV24c5hST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVXxOYdqUUN3ME2xNU45OiCwTR?=	MmnaV2FPT0WU
Mewo	NXPieVhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33Rc2lEPTB;MUGuPVkhdk1?	M1ewbHNCVkeHUh?=
HSC-3	M1zncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vtdWlEPTB;MUKuNlEhdk1?	NY\lU4w2W0GQR1XS
H4	MlnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3QfJREUUN3ME2xNk43PyCwTR?=	MXfTRW5ITVJ?
BB65-RCC	M123bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGC4XZBKSzVyPUGyMlczKG6P	MWTTRW5ITVJ?
NCI-H1793	M4rXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4TiRmlEPTB;MUKuPFIhdk1?	MV\TRW5ITVJ?
KARPAS-45	NVTOVmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{jlWWlEPTB;MUOuOVEhdk1?	MlO0V2FPT0WU
GCT	NFHCTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn30TWM2OD1zMz62PEBvVQ>?	M{CzTHNCVkeHUh?=
EoL-1	MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUPWSYduUUN3ME2xN{46OyCwTR?=	NGrwXW1USU6JRWK=
LB2241-RCC	NEHtcoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXPJR\|UxRTF2LkCxJI5O	MWDTRW5ITVJ?
ES5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fiSWlEPTB;MUSuO\|Qhdk1?	NH\5UJFUSU6JRWK=
LOXIMVI	NEXPR4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH;5dZVKSzVyPUG0Mlk6KG6P	MWXTRW5ITVJ?
COR-L105	NH:5WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3zfphKSzVyPUG1MlA1KG6P	Mn;kV2FPT0WU
P12-ICHIKAWA	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF3LkGgcm0>	MWrTRW5ITVJ?
CHL-1	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTF3LkS1JI5O	MVnTRW5ITVJ?
VMRC-RCZ	NXzUfIJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fVRWlEPTB;MUWuOlMhdk1?	M2OzcHNCVkeHUh?=
HH	MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnCT4RUUUN3ME2xOU44KG6P	M2noTnNCVkeHUh?=
NUGC-3	M{\tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnv2TWM2OD1zNj6zOEBvVQ>?	MkTiV2FPT0WU
EGI-1	NHPjSoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTNTWM2OD1zNj60N{BvVQ>?	M3PnO3NCVkeHUh?=
OS-RC-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmf0TWM2OD1zNj60O{BvVQ>?	MmTjV2FPT0WU
MOLT-16	M37BSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O3bmlEPTB;MUeuNVUhdk1?	NIL6d\|NUSU6JRWK=
NCI-H209	NVW5[HRsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjNS2xKSzVyPUG3MlI6KG6P	NGnoWFVUSU6JRWK=
697	NI\BfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDOfm9sUUN3ME2xO{41OyCwTR?=	M2PkRXNCVkeHUh?=
D-56MG	NVHWS\|RtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfhV4ZKSzVyPUG3MlY6KG6P	MYjTRW5ITVJ?
VA-ES-BJ	NYPZVHZLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIf4R\|FKSzVyPUG3Mlg{KG6P	NIL0cGFUSU6JRWK=
EW-16	NUTrSlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NULLUHlMUUN3ME2xPE4xPCCwTR?=	Mo[zV2FPT0WU
HGC-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4HPNGlEPTB;MUiuNFYhdk1?	NIPQUplUSU6JRWK=
ES7	M{\sUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF6LkC5JI5O	MV3TRW5ITVJ?
HuH-7	MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILMW5RKSzVyPUG4MlQhdk1?	NH7wXI5USU6JRWK=
BCPAP	Ml7IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Xre2lEPTB;MUiuOlUhdk1?	MX3TRW5ITVJ?
SW1710	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYDYN45ZUUN3ME2xPE44OiCwTR?=	Mn3pV2FPT0WU
IST-MEL1	NH3B[HFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHHTWM2OD1zOD63O{BvVQ>?	MoHHV2FPT0WU
SF295	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHHTWXRKSzVyPUG4Mlk{KG6P	NVXvWW1nW0GQR1XS
RPMI-7951	NH3HbWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFHDcnRKSzVyPUG5MlI5KG6P	MWXTRW5ITVJ?
SF126	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHznSHZKSzVyPUG5MlQyKG6P	NVPOO442W0GQR1XS
GAMG	M2\vO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPrcGlxUUN3ME2xPU41QCCwTR?=	NIfFXGhUSU6JRWK=
KNS-81-FD	NXPWXlc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vpSGlEPTB;MUmuOVQhdk1?	MoD0V2FPT0WU
RT-112	MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnjTWM2OD1zOT62OkBvVQ>?	M2fyW3NCVkeHUh?=
DEL	NG\FZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\STWM2OD1{MD60PUBvVQ>?	MUHTRW5ITVJ?
CGTH-W-1	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rlV2lEPTB;MkCuOlMhdk1?	NGDiWZNUSU6JRWK=
HOS	NIDhSohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIfMb\|NKSzVyPUKxMlA3KG6P	Mm\EV2FPT0WU
ES4	NYHJOpY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\a[JNKSzVyPUKxMlA5KG6P	Mor2V2FPT0WU
RXF393	NIjXO4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJzLkS1JI5O	NFnDbZpUSU6JRWK=
NCI-H2030	NETxOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;xOXk2UUN3ME2yNU42OiCwTR?=	NVTvPHlqW0GQR1XS
YH-13	NV3ETYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVn0cmtsUUN3ME2yNU45QCCwTR?=	NVPTNm9jW0GQR1XS
HT-1080	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PZS2lEPTB;MkGuPVMhdk1?	NEDJ[IpUSU6JRWK=
NCI-SNU-1	M3rnZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mkf3TWM2OD1{MT65OUBvVQ>?	NXj4WoVVW0GQR1XS
G-402	NV;LfVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\rSHNKSzVyPUKyMlE3KG6P	MVnTRW5ITVJ?
786-0	M{LKTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33ENmlEPTB;MkKuNlkhdk1?	Mme4V2FPT0WU
ME-180	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHe2eVZKSzVyPUKyMlQ{KG6P	NUnlWYlNW0GQR1XS
NB69	Moe0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7mTWM2OD1{Mj61N{BvVQ>?	NIDlemxUSU6JRWK=
J-RT3-T3-5	M1zndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mke0TWM2OD1{Mj65OkBvVQ>?	MljxV2FPT0WU
TGBC1TKB	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTJ\|LkC1JI5O	MlvXV2FPT0WU
SW780	NFL4XIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:zTWM2OD1{Mz6xN{BvVQ>?	NVG0UFhOW0GQR1XS
MG-63	M1rpd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWPreY1PUUN3ME2yN{41PSCwTR?=	NWe3T5RKW0GQR1XS
BV-173	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTJ\|Lki3JI5O	MXXTRW5ITVJ?
CAL-51	NFn4SWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XTemlEPTB;MkOuPFkhdk1?	MnzxV2FPT0WU
A375	M2[ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnPTWM2OD1{Mz65N{BvVQ>?	MWXTRW5ITVJ?
MEL-HO	MlnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jxZWlEPTB;MkSuNFQhdk1?	M1:4NXNCVkeHUh?=
EFO-27	M3X6WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUHJR\|UxRTJ2LkOzJI5O	MVLTRW5ITVJ?
Hs-578-T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmT0TWM2OD1{ND61PEBvVQ>?	NH\ydWRUSU6JRWK=
NBsusSR	M13kdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;tTmZGUUN3ME2yOE43KG6P	NGjVZlFUSU6JRWK=
CTB-1	Ml;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1eyW2lEPTB;MkSuOlchdk1?	NHruZWRUSU6JRWK=
FTC-133	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jhZWlEPTB;MkWuNUBvVQ>?	M{XzOHNCVkeHUh?=
MOLT-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTQSIxKSzVyPUK1MlEzKG6P	NUPkOFcyW0GQR1XS
HO-1-N-1	NInZXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PXbmlEPTB;MkWuNVUhdk1?	MYHTRW5ITVJ?
ES3	MmfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVvOeWZiUUN3ME2yOU4zOiCwTR?=	MVHTRW5ITVJ?
TI-73	NV\FT5Y5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XoU2lEPTB;MkWuNlghdk1?	Mn62V2FPT0WU
MPP-89	NGPQfHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTJ3LkOyJI5O	M{HMUHNCVkeHUh?=
KYSE-150	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1XLdWlEPTB;MkWuPFkhdk1?	NVzWfFNHW0GQR1XS
LXF-289	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M13JfGlEPTB;Mk[uNFQhdk1?	NYr6VIpyW0GQR1XS
SK-LU-1	NUnEOlFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7FTWM2OD1{Nj6xO{BvVQ>?	MX\TRW5ITVJ?
HOP-92	MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJ4LkS4JI5O	NVrQXplMW0GQR1XS
HuO9	NF[3[oRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnrjTWM2OD1{Nj63OkBvVQ>?	NIrtZ5BUSU6JRWK=
SW962	NWeweoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn7ETWM2OD1{Nj63OkBvVQ>?	M2XrV3NCVkeHUh?=
RS4-11	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHMUIZKSzVyPUK2MlkyKG6P	NX\HVFF3W0GQR1XS
NCI-H292	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTLXJZSUUN3ME2yO{BvVQ>?	NGLYXWpUSU6JRWK=
DB	NHzpXIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJ5LkO2JI5O	NH\qVpRUSU6JRWK=
SW1088	M4OyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTJ6LkK5JI5O	NV7Jcmp4W0GQR1XS
A204	NV:0eZJWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLBTWM2OD1{OD60O{BvVQ>?	M4DkT3NCVkeHUh?=
A3-KAW	NXHycpRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTJ6Lk[0JI5O	M1j5NnNCVkeHUh?=
MV-4-11	NIr5bHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTJ6Lkegcm0>	NF34WGZUSU6JRWK=
ES1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHGfmlxUUN3ME2yPE45PCCwTR?=	MoXVV2FPT0WU
ONS-76	NEDmT\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3xSFFKSzVyPUK5MlA2KG6P	M2\QOnNCVkeHUh?=
D-263MG	NIjrfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi0b2lKSzVyPUK5MlM2KG6P	NEjmNlNUSU6JRWK=
U-2-OS	NIfBfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFv1cHRKSzVyPUK5MlUhdk1?	NGDycJNUSU6JRWK=
T98G	NVzQO5lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELmZZdKSzVyPUK5Mlg5KG6P	MmXvV2FPT0WU
GI-ME-N	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTJ7LkmxJI5O	Mn7uV2FPT0WU
BHT-101	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXUSpVmUUN3ME2zNE4xPSCwTR?=	NGX4e3dUSU6JRWK=
NOS-1	Ml;2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nkVGlEPTB;M{CuNVIhdk1?	MX7TRW5ITVJ?
AsPC-1	M4K3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWS4WVY2UUN3ME2zNE4zKG6P	NUTj[mx3W0GQR1XS
QIMR-WIL	NVnhbm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPSTWM2OD1\|MD62JI5O	NIXKcJVUSU6JRWK=
JVM-3	M4PJcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHnONlhKSzVyPUOwMlg{KG6P	NYrydVVvW0GQR1XS
KU-19-19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\JR2lEPTB;M{GuNVMhdk1?	NFvSZ\|JUSU6JRWK=
OVCAR-8	NYfLNXJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVvGcVB3UUN3ME2zNU4zPiCwTR?=	NHr3PG5USU6JRWK=
BEN	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTNzLk[zJI5O	NWPuenp6W0GQR1XS
BE-13	NIq4UlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTNzLkiyJI5O	MV;TRW5ITVJ?
EW-18	NWHQ[4R{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4\NNGlEPTB;M{GuPFYhdk1?	M1jkXXNCVkeHUh?=
ECC10	NV64cXJCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnnnTWM2OD1\|MT65OUBvVQ>?	M2DXfnNCVkeHUh?=
CTV-1	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXm5UJp1UUN3ME2zNk45OiCwTR?=	MWnTRW5ITVJ?
COLO-800	NEHJOXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\mbGlEPTB;M{KuPVIhdk1?	NVnoOplHW0GQR1XS
A2058	M{H0cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTN\|LkK1JI5O	NHzHdVZUSU6JRWK=
VM-CUB-1	M3LoVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTN\|LkSzJI5O	NYD6T3RIW0GQR1XS
Ca9-22	NEK3NJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHH2TWFKSzVyPUOzMlU2KG6P	NWqyR3dQW0GQR1XS
COLO-684	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlj3TWM2OD1\|Mz61PEBvVQ>?	M3e5cXNCVkeHUh?=
RPMI-8226	MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1Wwe2lEPTB;M{OuPFIhdk1?	MV\TRW5ITVJ?
SK-NEP-1	M3\6Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV3tc2FuUUN3ME2zOE4yPSCwTR?=	NGWyVGlUSU6JRWK=
Becker	NF7GfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTN2LkKxJI5O	NHXsNFdUSU6JRWK=
NCI-H28	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGfk[I1KSzVyPUO0MlQ1KG6P	NGqzRodUSU6JRWK=
CAL-120	M4XhPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPJR\|UxRTN2LkeyJI5O	NEfiToJUSU6JRWK=
MDA-MB-157	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3rOOGlEPTB;M{WuOFEhdk1?	NFzCZppUSU6JRWK=
OVCAR-5	M2PIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLLTWM2OD1\|NT60O{BvVQ>?	NHW0dI5USU6JRWK=
LAMA-84	M3m0dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTN3Lki3JI5O	NYnsfFZZW0GQR1XS
CAKI-1	NUW5VIhET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN4LkSzJI5O	NIHXZ4pUSU6JRWK=
Daoy	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWqyWWd5UUN3ME2zOk44KG6P	MV3TRW5ITVJ?
CAL-62	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTEV2FrUUN3ME2zOk45PiCwTR?=	MnnmV2FPT0WU
8-MG-BA	M3XOUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUnJR\|UxRTN5LkK1JI5O	MUDTRW5ITVJ?
8505C	MlryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjRUVdKSzVyPUO3MlUyKG6P	NVT1VVZiW0GQR1XS
LNCaP-Clone-FGC	NIXTWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEC3eGNKSzVyPUO3MlU6KG6P	NYTjbWU1W0GQR1XS
CAL-39	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHrTWM2OD1\|Nz65JI5O	MWPTRW5ITVJ?
MN-60	NYfjbo1zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlP3TWM2OD1\|Nz65OkBvVQ>?	NU\ScVhxW0GQR1XS
RKO	NXPNUpZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTN6LkOzJI5O	NVHBc5BwW0GQR1XS
U251	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEG2dXFKSzVyPUO4MlQ{KG6P	MnvXV2FPT0WU
SJSA-1	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrrTWM2OD1\|OD61OEBvVQ>?	NEjHS3RUSU6JRWK=
CAL-12T	M3KzUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTN6Lk[gcm0>	NInDcJpUSU6JRWK=
HCC1419	NW\wfWV5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTN6LkexJI5O	MlrwV2FPT0WU
CO-314	NYfzSmQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXzRS4lEUUN3ME2zPE44PCCwTR?=	MnjBV2FPT0WU
LB1047-RCC	Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHmc2JKSzVyPUO4MlgyKG6P	NWe5c3p3W0GQR1XS
A101D	NVnHXmZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDZe5duUUN3ME2zPE46PyCwTR?=	M1XBVXNCVkeHUh?=
MDA-MB-175-VII	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3nmN2lEPTB;M{muOVEhdk1?	M1HQN3NCVkeHUh?=
MZ2-MEL	NXPGU4ZtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTN7Lk[2JI5O	MUXTRW5ITVJ?
NB5	MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTRyLk[0JI5O	MWXTRW5ITVJ?
G-401	M{TweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWDCSItUUUN3ME20NE45OiCwTR?=	M{fKWHNCVkeHUh?=
HT	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknyTWM2OD12MT6wNkBvVQ>?	MnjLV2FPT0WU
8305C	NYfvRldET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTRzLki3JI5O	NYH0XGZQW0GQR1XS
BHY	M330SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTR{LkeyJI5O	MWnTRW5ITVJ?
NTERA-S-cl-D1	Ml\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIKzNFBKSzVyPUSzJI5O	M1;hXHNCVkeHUh?=
T-24	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXnJR\|UxRTR\|LkizJI5O	M4XRW3NCVkeHUh?=
EPLC-272H	NYfWeYNIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[0OWlEPTB;NESuN\|khdk1?	NGPP[2xUSU6JRWK=
PSN1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\w[2lEPTB;NESuOEBvVQ>?	MljNV2FPT0WU
NCI-H2452	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnNUYFXUUN3ME20OE42QCCwTR?=	Mn2wV2FPT0WU
KS-1	MnX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnCUYNLUUN3ME20OE43PiCwTR?=	M2Cz[nNCVkeHUh?=
HD-MY-Z	NUXrOoRST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrnfFBKSzVyPUS0MlkzKG6P	NH;o[4ZUSU6JRWK=
KNS-62	NYHVUHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTR3LkO4JI5O	NH\XS2pUSU6JRWK=
NOMO-1	Ml\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\GdJM2UUN3ME20OU45PyCwTR?=	Ml73V2FPT0WU
SK-HEP-1	M1fEcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrKSlU{UUN3ME20Ok4xPCCwTR?=	MkTmV2FPT0WU
IGR-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV7JR\|UxRTR4LkGzJI5O	NGnpZodUSU6JRWK=
KYSE-180	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf0R\|IxUUN3ME20Ok4yPyCwTR?=	MYfTRW5ITVJ?
EW-22	M4ns[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTR4LkKgcm0>	NXXnOlg6W0GQR1XS
NCI-H1355	NIDxdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4i4SWlEPTB;NE[uN\|Qhdk1?	M{ToRXNCVkeHUh?=
DOHH-2	MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk[2TWM2OD12Nj6zO{BvVQ>?	M3T5U3NCVkeHUh?=
A4-Fuk	MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{nrdmlEPTB;NE[uOVIhdk1?	MkHQV2FPT0WU
PC-14	NUHPfWsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC5TWM2OD12Nj61O{BvVQ>?	MkjVV2FPT0WU
TE-5	MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHQWnhKSzVyPUS2Mlg1KG6P	MoPkV2FPT0WU
LB996-RCC	NEXvVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\z[YhKSzVyPUS3MlE6KG6P	MljBV2FPT0WU
NCI-H1623	NGrHeYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXFTWM2OD12Nz63OkBvVQ>?	NUXIfoNPW0GQR1XS
NCI-H1155	NHG5NWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX3JR\|UxRTR6LkOyJI5O	NEDOTnFUSU6JRWK=
LoVo	NHLYXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\uXZdKSzVyPUS4MlQhdk1?	M{T3S3NCVkeHUh?=
MCF7	NHX3UVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDzTWM2OD12OD61PEBvVQ>?	Mnm3V2FPT0WU
AGS	M1m4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPYSlFIUUN3ME20PE44PyCwTR?=	NIfifJdUSU6JRWK=
PFSK-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjWOohKSzVyPUS5MlA3KG6P	NEP2cnpUSU6JRWK=
22RV1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TsTGlEPTB;NEmuNFkhdk1?	M3K2PHNCVkeHUh?=
COR-L23	NUTDOmIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTR7LkG2JI5O	NW\RbWJjW0GQR1XS
D-283MED	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzRS5RLUUN3ME20PU43OSCwTR?=	M1LjXnNCVkeHUh?=
SW982	NVnBW2RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTR7LkmxJI5O	NYfDUJpMW0GQR1XS
SW620	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPjOXlKSzVyPUWwMlM3KG6P	NHzXepFUSU6JRWK=
KYSE-140	MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVL6OG5rUUN3ME21NE42PSCwTR?=	MWXTRW5ITVJ?
GCIY	M{m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmPNTWM2OD13MD62O{BvVQ>?	M3LmNnNCVkeHUh?=
MHH-ESS-1	NHXXUIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILieoxKSzVyPUWxMlk2KG6P	MkTMV2FPT0WU
D-423MG	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTtTWM2OD13Mj6wPEBvVQ>?	MYHTRW5ITVJ?
SF539	M4PwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jN[2lEPTB;NUKuN\|Uhdk1?	M3vHT3NCVkeHUh?=
RPMI-2650	NFXLT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTQR5JKSzVyPUWyMlY6KG6P	NXvwfGo6W0GQR1XS
GR-ST	Mn3ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIK0blNKSzVyPUWyMlg4KG6P	MoDPV2FPT0WU
YKG-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4\UXGlEPTB;NUOgcm0>	MXjTRW5ITVJ?
SK-MES-1	M4PzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFz2N41KSzVyPUWzMlI3KG6P	NHraNFNUSU6JRWK=
HLE	NIG5boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnVTWM2OD13Mz60O{BvVQ>?	NUOxc2NMW0GQR1XS
RVH-421	NEnIfnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkfETWM2OD13Mz62O{BvVQ>?	M{XUdnNCVkeHUh?=
C32	M3[5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrmb2s{UUN3ME21N{45OyCwTR?=	MYrTRW5ITVJ?
GB-1	M{O2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYLJR\|UxRTV2LkKgcm0>	NGLzcoNUSU6JRWK=
SNB75	MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TQXWlEPTB;NUSuNlYhdk1?	NELHTFlUSU6JRWK=
EM-2	NXjOTIRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTV2LkSgcm0>	NVrkV3VMW0GQR1XS
RH-1	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\sZmVKSzVyPUW0Mlchdk1?	M1Lj[nNCVkeHUh?=
NKM-1	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH[z[HJKSzVyPUW0MlgyKG6P	NWLHWlJ5W0GQR1XS
NCI-H2405	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX[0eWRnUUN3ME21OE45QCCwTR?=	NGXXWGlUSU6JRWK=
KYSE-450	NIfPWoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPyTWM2OD13NT6xOkBvVQ>?	M1zo[3NCVkeHUh?=
A704	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVPBdolXUUN3ME21OU42QSCwTR?=	NX:3T5ZCW0GQR1XS
HAL-01	NIfBSmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUf6XYM3UUN3ME21OU45OyCwTR?=	NUe2b\|lCW0GQR1XS
TE-11	NWjlZ5lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;lRmlEPTB;NUWuPVkhdk1?	M2fBdHNCVkeHUh?=
DOK	NIPCOGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXZTWM2OD13Nj6wNkBvVQ>?	NV3KWoM4W0GQR1XS
KY821	NIG2SHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13NV2lEPTB;NU[uNkBvVQ>?	MX7TRW5ITVJ?
KGN	MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fTSGlEPTB;NU[uN\|Ihdk1?	NInk[WpUSU6JRWK=
MC116	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\aZYhKSzVyPUW3Mlghdk1?	MmT4V2FPT0WU
PANC-08-13	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mni0TWM2OD13OD6wNUBvVQ>?	MmKzV2FPT0WU
KE-37	NYTzZlQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPjb2xEUUN3ME21PE44PyCwTR?=	NYr2b5hrW0GQR1XS
KYSE-410	NIjiU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXZUm5KSzVyPUW5MlQ4KG6P	MV7TRW5ITVJ?
RO82-W-1	M{TIe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVmyR3d5UUN3ME21PU46KG6P	NH[yTXlUSU6JRWK=
M14	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn:2TWM2OD14MD6wOEBvVQ>?	M2\vcHNCVkeHUh?=
GI-1	NXv4PWQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2npOGlEPTB;NkCuN{BvVQ>?	MWrTRW5ITVJ?
ML-2	NVvqVmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTZyLk[yJI5O	NXu0fmk3W0GQR1XS
BFTC-905	M1zpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{Ly[2lEPTB;NkCuOlUhdk1?	NXnKVGxyW0GQR1XS
DMS-273	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjzcY9KSzVyPU[wMlg4KG6P	MVnTRW5ITVJ?
MDA-MB-361	M2S0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKwcVNKSzVyPU[xJI5O	NGnPRYdUSU6JRWK=
MSTO-211H	NWHu[HBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnvXTWM2OD14Mz61NUBvVQ>?	NX3ZXHptW0GQR1XS
MEG-01	NXPnVVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTZ\|LkWyJI5O	M{nXZnNCVkeHUh?=
M059J	NHLEcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\Hd2lEPTB;NkOuOVghdk1?	M4jDOXNCVkeHUh?=
LN-405	NInMfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTU[lJKUUN3ME22N{45PSCwTR?=	MojXV2FPT0WU
NCI-H1581	M1zhc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVHxSm16UUN3ME22OE4xOyCwTR?=	NHHrOJZUSU6JRWK=
TCCSUP	NXjrO\|J1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHfQZY1KSzVyPU[0MlU{KG6P	M1XSd3NCVkeHUh?=
SW872	NIXxUnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPFdmpWUUN3ME22OE42PyCwTR?=	M3rFfnNCVkeHUh?=
KYSE-510	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;Nd29KSzVyPU[1Mlc2KG6P	NH\wfZFUSU6JRWK=
NCI-H1792	NVnZVmUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTZ4LkG1JI5O	MoDJV2FPT0WU
SW13	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUD3NmlWUUN3ME22Ok42KG6P	MWTTRW5ITVJ?
TE-8	MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfQNlFKSzVyPU[2MlUzKG6P	NXHROXROW0GQR1XS
SCH	Mn7NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3y1TGlEPTB;NkeuNUBvVQ>?	MmDEV2FPT0WU
NEC8	NHnxe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{jrdGlEPTB;NkeuNlQhdk1?	NXTIWVE6W0GQR1XS
HuO-3N1	NF;Nb2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTZ5LkOxJI5O	NXHQN2pEW0GQR1XS
EFM-19	NH3nRnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTZ5LkWgcm0>	NIjEUphUSU6JRWK=
HEC-1	NFvjZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGq3XWRKSzVyPU[3MlUzKG6P	MYXTRW5ITVJ?
T47D	MkXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nW[mlEPTB;NkeuPFchdk1?	M{ezWHNCVkeHUh?=
SNU-423	NHnvcZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTOTWM2OD14Nz65PEBvVQ>?	MmjxV2FPT0WU
WM-115	NUjxd3U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFTBe5VKSzVyPU[4MlE1KG6P	M3;0NHNCVkeHUh?=
CaR-1	M{\wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTW[mxKSzVyPU[4MlI2KG6P	NV2zdoxzW0GQR1XS
KU812	NHq4[G9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjBXoRKSzVyPU[4MlY6KG6P	MofxV2FPT0WU
AM-38	M1n2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTZ7LkOxJI5O	M1jodXNCVkeHUh?=
KOSC-2	NYCzbWRvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\MTWM2OD14OT65O{BvVQ>?	M4TZZXNCVkeHUh?=
MC-IXC	M4C1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDoNFdXUUN3ME23NE4xQCCwTR?=	M2n4[HNCVkeHUh?=
SCC-4	NEewWJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13kNGlEPTB;N{GuN\|ghdk1?	MlfhV2FPT0WU
Calu-3	NFvqWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnzWJQyUUN3ME23NU46QCCwTR?=	MYrTRW5ITVJ?
RPMI-8866	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjoTpZJUUN3ME23Nk45OiCwTR?=	MnewV2FPT0WU
OVCAR-4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4fKXWlEPTB;N{OuN\|Yhdk1?	MXzTRW5ITVJ?
OAW-42	NGq1NXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlHWTWM2OD15Mz6zPUBvVQ>?	NXywfZR3W0GQR1XS
ATN-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGnqOZNKSzVyPUezMlg4KG6P	NFr5WXVUSU6JRWK=
CHP-212	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\KUFNKSzVyPUe0Mlk2KG6P	NEHveotUSU6JRWK=
C2BBe1	MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1facmlEPTB;N{WuNFMhdk1?	NFmyS4ZUSU6JRWK=
A498	NWjTcoM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmP3TWM2OD15NT6xOUBvVQ>?	MWXTRW5ITVJ?
SH-4	MmGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7uTWM2OD15NT6yNUBvVQ>?	Mmj2V2FPT0WU
SNU-449	NYXRXY42T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;CWHVKSzVyPUe1Mlc6KG6P	MojEV2FPT0WU
RD	NGDZOGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPKOlBKSzVyPUe1Mlg3KG6P	NIfuWZhUSU6JRWK=
PANC-03-27	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1u0dWlEPTB;N{[uNlUhdk1?	NWDpOmdVW0GQR1XS
S-117	MmfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfDTWM2OD15Nj6yO{BvVQ>?	Mn3RV2FPT0WU
SK-MEL-2	Mlv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\wNWlEPTB;N{[uO\|Uhdk1?	Mm\DV2FPT0WU
LK-2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLKTWM2OD15Nz6wOUBvVQ>?	MnfGV2FPT0WU
CP50-MEL-B	M4jrZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU[0ZXF{UUN3ME23O{41KG6P	MXPTRW5ITVJ?
647-V	NHGzZ5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfrNWJSUUN3ME23PE4xPyCwTR?=	NXTCbJhIW0GQR1XS
LU-134-A	M2PFd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2H3eWlEPTB;N{muNFMhdk1?	MXHTRW5ITVJ?
5637	MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTd7LkKzJI5O	NUnhV2IyW0GQR1XS
NCI-H1437	M4\sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUHsc4wyUUN3ME24NE42KG6P	M3fNfXNCVkeHUh?=
NCI-H460	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTDPHpWUUN3ME24NU4zOyCwTR?=	NXnWbGgxW0GQR1XS
BxPC-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYfae\|ZLUUN3ME24NU41PiCwTR?=	MX\TRW5ITVJ?
CAN	M4XpZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUjJR\|UxRThzLki0JI5O	MVXTRW5ITVJ?
KINGS-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4DuT2lEPTB;OEKuN\|Ihdk1?	NEnwV5JUSU6JRWK=
OCUB-M	MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV7JR\|UxRTh{LkSxJI5O	M4rIcnNCVkeHUh?=
KALS-1	MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHeyZWVKSzVyPUiyMlU1KG6P	M{XLO3NCVkeHUh?=
OCI-AML2	NYfYZZNOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTh{Lk[xJI5O	NWfadI5yW0GQR1XS
A253	NUCy[4lCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjWbpZRUUN3ME24Nk43PSCwTR?=	MlPMV2FPT0WU
LCLC-97TM1	M33Y[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXhTWM2OD16Mj64OkBvVQ>?	NH7seIRUSU6JRWK=
NCI-H520	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFGxNFBKSzVyPUizMlA3KG6P	NVr4PXpFW0GQR1XS
P30-OHK	Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTh\|LkWgcm0>	NGXqO4lUSU6JRWK=
SBC-5	NXztbZUzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2nPVmlEPTB;OEOuOVIhdk1?	NGCzVYhUSU6JRWK=
HCE-T	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYP4V\|lRUUN3ME24N{44PCCwTR?=	MXjTRW5ITVJ?
JEG-3	MoK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTh2LkGgcm0>	MoD3V2FPT0WU
KG-1	M17CUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\Jd4EzUUN3ME24OE4zPCCwTR?=	M1fwWnNCVkeHUh?=
MIA-PaCa-2	MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTh2LkW0JI5O	MX7TRW5ITVJ?
CAL-33	M{LaeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTRUnlEUUN3ME24OU4xQCCwTR?=	NGfLbXpUSU6JRWK=
639-V	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTh3LkSyJI5O	NYq4d\|NxW0GQR1XS
NCI-H1048	NI\kOINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnJR\|UxRTh4LkOxJI5O	NFvLSYVUSU6JRWK=
NCI-H1573	NXfvfGR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH35V5JKSzVyPUi3MlQ5KG6P	NF;3NXFUSU6JRWK=
NCI-H2228	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\FSWlEPTB;OEiuNlYhdk1?	MnL4V2FPT0WU
NB14	MlHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPtdWpKSzVyPUi4MlMhdk1?	MWrTRW5ITVJ?
SCC-25	MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jH[WlEPTB;OEmuPFIhdk1?	M4LudHNCVkeHUh?=
A431	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1LzTmlEPTB;OEmuPVchdk1?	NH;wdlRUSU6JRWK=
SN12C	MlT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWDS[I9EUUN3ME25NE43OiCwTR?=	NFG4fppUSU6JRWK=
HuCCT1	NHe1[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUG0eXd7UUN3ME25NE44PiCwTR?=	NVfme5NpW0GQR1XS
LS-123	MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4O2UWlEPTB;OUKuNVghdk1?	MVrTRW5ITVJ?
CAL-85-1	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvPTWM2OD17Mj60PEBvVQ>?	NWDDNGM1W0GQR1XS
ES6	M{j2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rpOGlEPTB;OUKuPFMhdk1?	NH3VWJBUSU6JRWK=
NCI-H650	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrENIVTUUN3ME25OE4xQSCwTR?=	NHnNdYtUSU6JRWK=
NCI-H446	M4fteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUfJR\|UxRTl3LkGyJI5O	NVLSVHlCW0GQR1XS
EW-13	M2O5TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzJTWM2OD17NT63OUBvVQ>?	NHri[\|dUSU6JRWK=
HSC-2	NIrM[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfQTWM2OD17NT64PUBvVQ>?	NIfuN5VUSU6JRWK=
U031	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTl4LkezJI5O	MlL6V2FPT0WU
EW-11	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX3JR\|UxRTl4Lki4JI5O	NFTGbpdUSU6JRWK=
GAK	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4SyOGlEPTB;OUiuPVMhdk1?	MkjKV2FPT0WU
SK-OV-3	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnzSTWM2OD1zMECuNFchdk1?	Ml\xV2FPT0WU
OMC-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYSwZWltUUN3ME2xNFAvOThibl2=	NUO3[3lPW0GQR1XS
TK10	NH7yVGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nnbWlEPTB;MUCwMlIyKG6P	NGPDdGVUSU6JRWK=
EKVX	M2HPXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;EZ\|JKSzVyPUGwNE43KG6P	M4Hpe3NCVkeHUh?=
Detroit562	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTFyMj6xO{BvVQ>?	M3v1cHNCVkeHUh?=
SF268	Mnm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmK3TWM2OD1zMEKuN\|Qhdk1?	NHrWbVRUSU6JRWK=
SNU-387	Ml:0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjzTWM2OD1zMESuNVchdk1?	NF3uUpBUSU6JRWK=
MDA-MB-231	NYHWSml{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTFyNT6wOkBvVQ>?	NU\tTmVUW0GQR1XS
NCI-H1563	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPpTWM2OD1zMEWuNVghdk1?	MVTTRW5ITVJ?
D-502MG	M1zwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTFyNT63JI5O	NVTZSpdEW0GQR1XS
A2780	NX7JfWJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfW[Y1KSzVyPUGwOk41PyCwTR?=	MmPpV2FPT0WU
IA-LM	NGjaRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\PcWlEPTB;MUC3MlUyKG6P	MYDTRW5ITVJ?
D-392MG	Mne4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NITWTnZKSzVyPUGwO{42PCCwTR?=	MmrvV2FPT0WU
MS-1	NHnPUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWGyNGVmUUN3ME2xNFcvPzFibl2=	M1zGZXNCVkeHUh?=
SW1990	MofJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUm5SI1ZUUN3ME2xNFgvPTRibl2=	M4\TUXNCVkeHUh?=
HEL	M{X6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGm5SIlKSzVyPUGwPU4zQSCwTR?=	NFu5VpJUSU6JRWK=
SW1573	NULybo1XT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXRZYxKSzVyPUGwPU4{OSCwTR?=	MVrTRW5ITVJ?
SW1783	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVTncWQyUUN3ME2xNVAvOjJibl2=	M3S5W3NCVkeHUh?=
COLO-680N	NVTzblBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LKNmlEPTB;MUGwMlc3KG6P	MX\TRW5ITVJ?
NCI-N87	NXLzc5RwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTFzMT6wOEBvVQ>?	Mof0V2FPT0WU
SK-MEL-28	M4r2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXP2UXJzUUN3ME2xNVEvPTVibl2=	M1fZc3NCVkeHUh?=
BT-20	NYLnRVVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWO4N4ZIUUN3ME2xNVIvODFibl2=	NWfCemEzW0GQR1XS
NCI-H1648	NWDsNGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2P2b2lEPTB;MUGzJI5O	NEPpZoZUSU6JRWK=
no-11	NIjNNnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NG\1e5pKSzVyPUGxN{4zQCCwTR?=	MUjTRW5ITVJ?
MOLT-13	Ml;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFzMz60OEBvVQ>?	NEjxV4pUSU6JRWK=
NCI-H2170	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPNcZJKSzVyPUGxOE42OSCwTR?=	NUHrTo1MW0GQR1XS
HTC-C3	NGrEcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnGTJJKSzVyPUGxOk45PSCwTR?=	MWTTRW5ITVJ?
LU-99A	M3T1OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX3lSG1MUUN3ME2xNVcvOjFibl2=	NHfpVYhUSU6JRWK=
HCC2998	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjWTWM2OD1zMUeuPVIhdk1?	M1LvXHNCVkeHUh?=
NB13	M3jUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnu3TWM2OD1zMUeuPVkhdk1?	MWjTRW5ITVJ?
GT3TKB	M3XC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fhXmlEPTB;MUG4MlA5KG6P	NY\tb2F7W0GQR1XS
BT-549	MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M160eGlEPTB;MUG4Mlk2KG6P	NVHvfWNyW0GQR1XS
NCI-H747	M1XsR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFS5TIxKSzVyPUGxPU4{PCCwTR?=	MX\TRW5ITVJ?
EW-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XGemlEPTB;MUKwMlIhdk1?	Mlr3V2FPT0WU
LB831-BLC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXwO4NKSzVyPUGyNE43OyCwTR?=	MVTTRW5ITVJ?
NMC-G1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELmc5FKSzVyPUGyNU4yOSCwTR?=	Moj3V2FPT0WU
COLO-679	M1rHWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXO3R2k5UUN3ME2xNlIvOTVibl2=	MYnTRW5ITVJ?
HL-60	NXLCXItTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEnISoxKSzVyPUGyN{4yKG6P	MXvTRW5ITVJ?
MKN7	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTF{Mz64N{BvVQ>?	NXf2e4FSW0GQR1XS
RERF-LC-MS	NH\Y[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF{ND6zNUBvVQ>?	MlG1V2FPT0WU
DMS-114	M4DCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGG0UYNKSzVyPUGyOU4xQSCwTR?=	M3PQZXNCVkeHUh?=
HuP-T4	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHuTVRKSzVyPUGyOk46PyCwTR?=	M2PCW3NCVkeHUh?=
HCC2157	NF;pcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVW4UYZsUUN3ME2xNlcvPSCwTR?=	NXmzfVAyW0GQR1XS
SKG-IIIa	MmHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{i5SmlEPTB;MUK4Mlghdk1?	M17ZV3NCVkeHUh?=
HCT-116	NXS5bXJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXnJR\|UxRTF\|MD62OEBvVQ>?	MnXZV2FPT0WU
BB30-HNC	NUjQU3dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTF\|MD63PEBvVQ>?	M2HjRXNCVkeHUh?=
KYSE-270	NYC1S2ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MULJR\|UxRTF\|MD64PEBvVQ>?	NV7kN3E2W0GQR1XS
MFM-223	MmrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUO1NVBTUUN3ME2xN\|EvPTFibl2=	MWXTRW5ITVJ?
NH-12	NXTDcXVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DpWWlEPTB;MUOyMlk6KG6P	NXLUSm5QW0GQR1XS
U-118-MG	NE[5PXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHOTWM2OD1zM{OuOlIhdk1?	M4\ZeXNCVkeHUh?=
ESS-1	NWLCT3VmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF\|NT6xPEBvVQ>?	NYLHPZRZW0GQR1XS
D-247MG	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3TCV2lEPTB;MUO1MlIyKG6P	MYfTRW5ITVJ?
IGROV-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\iN4U1UUN3ME2xN\|UvPzZibl2=	NUHjfYhuW0GQR1XS
C-33-A	M33jWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVvrRoU1UUN3ME2xN\|UvQTdibl2=	M2PPOnNCVkeHUh?=
NCI-H1693	NWWxPIMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDudXRRUUN3ME2xN\|YvOTJibl2=	NGPvdJpUSU6JRWK=
MLMA	M3;aeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPkPVJKSzVyPUGzOk42QCCwTR?=	MlnVV2FPT0WU
SK-N-AS	NEfqOmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoDpTWM2OD1zM{euNVchdk1?	MUPTRW5ITVJ?
NCI-H1755	M2\jWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrCb5NLUUN3ME2xN\|gvQDVibl2=	M4nlenNCVkeHUh?=
CHP-134	MlXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUf0XI5mUUN3ME2xN\|kvPTVibl2=	M1fkRXNCVkeHUh?=
LS-513	NH3OdXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTF2MD65NUBxVQ>?	NVTKT21qW0GQR1XS
TE-12	M2HFbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPPOHVPUUN3ME2xOFAvQTNibl2=	NWey[VRDW0GQR1XS
KNS-42	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonjTWM2OD1zNESuN{BvVQ>?	NEf2NVVUSU6JRWK=
SJRH30	NWCwRYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVHyepBVUUN3ME2xOFQvPDRibl2=	NV;0[5BQW0GQR1XS
NCI-H1092	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3z2NmlEPTB;MUS0MlUzKG6P	MX3TRW5ITVJ?
H-EMC-SS	NE\VRnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVn0dVlyUUN3ME2xOFYvQDFibl2=	NGC0fVdUSU6JRWK=
SK-MEL-3	NWDxR3lVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIHi[m1KSzVyPUG0O{42PSCwTR?=	NFP5XHJUSU6JRWK=
SK-N-FI	MnnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3rDWmlEPTB;MUS3MlU6KG6P	MXXTRW5ITVJ?
NCI-H2126	NX\1ZXE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWT0NXpDUUN3ME2xOFgvOTVibl2=	MnXQV2FPT0WU
NCI-H1299	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe2e2xKSzVyPUG1NE4zOiCwTR?=	NHHp[nNUSU6JRWK=
CFPAC-1	M3iwdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTF3MD62OkBvVQ>?	MkLlV2FPT0WU
NCI-H661	MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTF3MT6yOkBvVQ>?	M4HnbHNCVkeHUh?=
KYSE-70	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHXmWlNKSzVyPUG1NU44QSCwTR?=	MkPxV2FPT0WU
SW900	MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVGzZnRbUUN3ME2xOVQvPjVibl2=	NILWZmZUSU6JRWK=
Ca-Ski	NXnvcHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HndWlEPTB;MUW2MlM6KG6P	MmDoV2FPT0WU
HPAF-II	M4HVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvoTWM2OD1zNU[uOFchdk1?	NXrBdFdMW0GQR1XS
LB2518-MEL	NVHPVndET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRTF3Nz6xJI5O	MmiwV2FPT0WU
LC-2-ad	MlLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;scVFKSzVyPUG1PE43OiCwTR?=	MkLDV2FPT0WU
HCC1806	M4\ZfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGK2XJVKSzVyPUG2O{45QCCwTR?=	MYnTRW5ITVJ?
UACC-62	M1T4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXLTeW5RUUN3ME2xOlgvODlibl2=	NF\NPI1USU6JRWK=
KM-H2	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTF5MD61PEBvVQ>?	M1;HbnNCVkeHUh?=
NCI-H2347	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV;McpFEUUN3ME2xO\|IvPzJibl2=	M2rtfnNCVkeHUh?=
SCC-15	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{jkSGlEPTB;MUezMlY3KG6P	MYrTRW5ITVJ?
BB49-HNC	NF7Wd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTF5Mz64NUBvVQ>?	MVzTRW5ITVJ?
GMS-10	NEDROHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWrJR\|UxRTF5Mz65OEBvVQ>?	MlztV2FPT0WU
NCI-H2052	M2DoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTF5ND65JI5O	NILMcJVUSU6JRWK=
SW626	NEnlRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml[4TWM2OD1zN{[uNFYhdk1?	NEXSOW1USU6JRWK=
MDA-MB-415	MoDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTMTWM2OD1zN{[uOlEhdk1?	MYXTRW5ITVJ?
Saos-2	MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPqR3FOUUN3ME2xO\|kvOzVibl2=	M{LW[3NCVkeHUh?=
DK-MG	NUHYU4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\1TWM2OD1zOECuN{BvVQ>?	NEHaeIxUSU6JRWK=
SNU-C2B	NXPhbZp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTF6MD63N{BvVQ>?	Mk\QV2FPT0WU
A427	NXq1Z49rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVfFcGVtUUN3ME2xPFIvPTdibl2=	M3jhZnNCVkeHUh?=
KP-N-YS	M4fYWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXfJR\|UxRTF6NTDuUS=>	NV3MRo9RW0GQR1XS
J82	NGTpclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIr5RXRKSzVyPUG4OU4yQCCwTR?=	M3nXenNCVkeHUh?=
LS-411N	NH7G[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmSwTWM2OD1zOEeuNlghdk1?	M4jV[HNCVkeHUh?=
HCC1937	NHrOV\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkTzTWM2OD1zOEeuOFkhdk1?	M1:3SHNCVkeHUh?=
OE33	MlrGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\DRXFKSzVyPUG4PE46PyCwTR?=	MkKzV2FPT0WU
NB7	NYPuU3ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XISWlEPTB;MUi5Mlg6KG6P	M{i0OHNCVkeHUh?=
SW684	M2DLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfPTWM2OD1zOU[uNVMhdk1?	M2DUUnNCVkeHUh?=
HT-144	NIDUNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlfmTWM2OD1zOU[uNVUhdk1?	MnnkV2FPT0WU
SK-MEL-30	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jaRmlEPTB;MUm2MlIhdk1?	MmDWV2FPT0WU
DBTRG-05MG	NGPaPGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTF7OD60O{BvVQ>?	M17ydHNCVkeHUh?=
NCI-H1395	NF;X[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXHd3puUUN3ME2xPVgvQDVibl2=	M3zIW3NCVkeHUh?=
NCI-H2122	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJyMD61PUBvVQ>?	NVHQbWI2W0GQR1XS
no-10	M3n6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjmW5dKSzVyPUKwNU4xPCCwTR?=	M4\hbnNCVkeHUh?=
SW48	MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7PVplNUUN3ME2yNFEvOzFibl2=	NF;XcHBUSU6JRWK=
NCI-H1650	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHBWYo5UUN3ME2yNFQvODFibl2=	M1XxUHNCVkeHUh?=
MZ1-PC	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHvwXmFKSzVyPUKwOU42QCCwTR?=	M3T2b3NCVkeHUh?=
U-266	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zMUmlEPTB;MkC1Mlc6KG6P	NFLoU4tUSU6JRWK=
CAS-1	M4rOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLWTWM2OD1{MEeuOFQhdk1?	NHz1NmVUSU6JRWK=
AU565	M2D5XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDsTWM2OD1{MUKuPFIhdk1?	NWrlWFIyW0GQR1XS
UACC-257	M2D1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXiTWM2OD1{MUOuPVkhdk1?	NV2xS5dYW0GQR1XS
CAL-27	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVzYN\|l6UUN3ME2yNVcvODVibl2=	NXfkTXZ[W0GQR1XS
NCI-H23	NXPwVHdKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGL5TIhKSzVyPUKxPU4{OyCwTR?=	NF3Xd4tUSU6JRWK=
TE-6	NFXOU5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vMZ2lEPTB;MkG5MlY5KG6P	NYO2Z2lOW0GQR1XS
TGBC24TKB	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3qwbWlEPTB;MkKyMlE4KG6P	NGP0Z\|FUSU6JRWK=
TE-1	NWLQdpJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTJ{Mj64PEBvVQ>?	NEfNcHhUSU6JRWK=
RCC10RGB	MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmnsTWM2OD1{MkSuNVkhdk1?	MYHTRW5ITVJ?
NCI-H596	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWrGR5RxUUN3ME2yNlgvOjJibl2=	NYfWfIVuW0GQR1XS
SW954	NYPUW41mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVPJR\|UxRTJ\|Mz64N{BvVQ>?	NV;QcoZsW0GQR1XS
NCI-H2087	NX;HPItDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jrc2lEPTB;MkO0MlUyKG6P	NFPRXlBUSU6JRWK=
SK-PN-DW	M3LYO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\vTml[UUN3ME2yN\|UvOTlibl2=	NVjyfHBvW0GQR1XS
KM12	MlTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{Cy[WlEPTB;MkO1Mlchdk1?	NXXiUoJKW0GQR1XS
BT-474	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUW5NY5GUUN3ME2yN\|UvPzNibl2=	MWLTRW5ITVJ?
IST-MES1	NULtWYNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfiTWM2OD1{M{[uOVchdk1?	NEH4ZWNUSU6JRWK=
HT-1197	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ\|OD6wPUBvVQ>?	NV2wUmlCW0GQR1XS
CAL-54	NVLneI5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{HUVGlEPTB;MkO4MlQ6KG6P	M3fHSXNCVkeHUh?=
NB10	M4fNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTJ2MD6wOkBvVQ>?	MkOyV2FPT0WU
PANC-10-05	NW\hOIxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV\JR\|UxRTJ2NT61OkBvVQ>?	MW\TRW5ITVJ?
NCI-H522	NX76PFZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfhcpFKSzVyPUK0PE4{OSCwTR?=	Ml71V2FPT0WU
A388	M{i1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDIS5ZmUUN3ME2yOFkvQDJibl2=	MUPTRW5ITVJ?
GOTO	MknHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nte2lEPTB;MkWwMlI6KG6P	MUjTRW5ITVJ?
KLE	NFvIeIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXLdJJmUUN3ME2yOVEvQDdibl2=	MkXHV2FPT0WU
KYSE-520	NEHhe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HVdmlEPTB;MkWyMlg3KG6P	M4C3cHNCVkeHUh?=
HCE-4	NFztV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vrZWlEPTB;Mk[yMlUhdk1?	M2XrUXNCVkeHUh?=
KURAMOCHI	NWnvWoRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjseVJKUUN3ME2yOlUvQSCwTR?=	MkP3V2FPT0WU
HCC38	MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDBNZBRUUN3ME2yOlYvPDhibl2=	MYDTRW5ITVJ?
FADU	NXHFdFM4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\uTWM2OD1{Nk[uOlMhdk1?	Mn3WV2FPT0WU
CW-2	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTJ4OT65OkBvVQ>?	M4KxcnNCVkeHUh?=
L-428	M{P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlLiTWM2OD1{N{WuNVUhdk1?	M1XF[3NCVkeHUh?=
HCC1569	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n2[GlEPTB;Mke1Mlg1KG6P	NHfsO2ZUSU6JRWK=
NCI-H810	Moj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHS5N\|RKSzVyPUK3PE4{OSCwTR?=	M1LvWXNCVkeHUh?=
LB771-HNC	M3TSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTJ6NT64OEBvVQ>?	NIjKeZVUSU6JRWK=
LCLC-103H	NWOzNm86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJ6NT65PUBvVQ>?	NUjT[4Z2W0GQR1XS
EFO-21	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXrJR\|UxRTJ6Nz62PEBvVQ>?	NEfw[WFUSU6JRWK=
CAL-72	NEXz[IxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\ZOWlEPTB;MkmzMlE6KG6P	M4XqPHNCVkeHUh?=
SCC-9	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7lbHZKSzVyPUK5N{4zOiCwTR?=	NFXr[lFUSU6JRWK=
COLO-829	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37oRWlEPTB;Mkm2MlUhdk1?	NIL3NGNUSU6JRWK=
U-87-MG	NVLTW5A6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX\JR\|UxRTNyMD63N{BvVQ>?	NGrqZWRUSU6JRWK=
MZ7-mel	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDU[o1PUUN3ME2zNlMvPzZibl2=	MlHkV2FPT0WU
NCI-H1770	NXvFWmV{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;admVKSzVyPUOyOk44PCCwTR?=	M3:zXnNCVkeHUh?=
ChaGo-K-1	NEjyOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\sSpdKSzVyPUOyPE4yKG6P	NIfLbXNUSU6JRWK=
SiHa	NUfwbnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTN{OT6yOEBvVQ>?	Mn3JV2FPT0WU
NCI-SNU-5	MknsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIq4SYJKSzVyPUOzOk44PyCwTR?=	MoXIV2FPT0WU
DJM-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXlTWM2OD1\|NECuN\|Mhdk1?	M4jsZXNCVkeHUh?=
OE19	NH;ncGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXsXpVCUUN3ME2zOFAvPTNibl2=	MljOV2FPT0WU
NCI-H1651	M3rqUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDneJZKSzVyPUO0OE4yQCCwTR?=	MnntV2FPT0WU
COLO-792	NWraPJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1PFNGlEPTB;M{W0MlQzKG6P	MkP4V2FPT0WU
ACHN	NYPZUoRxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHznTYFKSzVyPUO1Ok44OSCwTR?=	MlfLV2FPT0WU
TH-3	M{jITmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PDfGlEPTB;M{e5Mlk2KG6P	Mli0V2FPT0WU
HT-1376	NYTFW\|ByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\hTWM2OD1\|OESuPFghdk1?	NFrw[\|RUSU6JRWK=
RH-18	M3ny[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV[wdVh7UUN3ME2zPVQvPzRibl2=	NXfudXdrW0GQR1XS
NB6	MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnpUYluUUN3ME2zPVYvPjZibl2=	NH;xZpNUSU6JRWK=
COLO-320-HSR	NV7veFB4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoH1TWM2OD12MEOuN\|chdk1?	NWD6R5JFW0GQR1XS
UACC-893	NXPpcmxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlG2TWM2OD12ME[uOFchdk1?	MVfTRW5ITVJ?
DSH1	M{PVUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHKSY9iUUN3ME20NFYvQTFibl2=	M33RRnNCVkeHUh?=
TE-10	NH7teG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVrJR\|UxRTRyNz6wNUBvVQ>?	MljmV2FPT0WU
HCC70	NHrYVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTRyOT6yNUBvVQ>?	NFzSenhUSU6JRWK=
TGBC11TKB	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4CyNGlEPTB;NEGwMlM{KG6P	MkDQV2FPT0WU
NCI-H727	NFzRfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1v2bWlEPTB;NEGyMlEyKG6P	NXexboNDW0GQR1XS
ALL-PO	NYTpN\|B1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDvV4J[UUN3ME20NVUvPjlibl2=	MYfTRW5ITVJ?
ABC-1	NELs[WZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlL2TWM2OD12MkCuOFUhdk1?	MYHTRW5ITVJ?
NCI-H69	NISzbXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[zXmlEPTB;NEK2Mlc3KG6P	NFezZWRUSU6JRWK=
GP5d	NXHrdVZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljzTWM2OD12M{SuOFEhdk1?	M37pcnNCVkeHUh?=
UMC-11	NYPO[lNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTR3OD6zOkBvVQ>?	MUDTRW5ITVJ?
RMG-I	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTR4Nz61OkBvVQ>?	MXTTRW5ITVJ?
YAPC	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTR7MD62JI5O	MkCyV2FPT0WU
LS-1034	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTR7MT6wOkBvVQ>?	NVPOb\|hJW0GQR1XS
RCM-1	NFzBZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrDTWM2OD12OU[uOlghdk1?	MX;TRW5ITVJ?
HCC1954	MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWTZTIJnUUN3ME21NVIvPSCwTR?=	M2PxdXNCVkeHUh?=
SK-MEL-24	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2P0eGlEPTB;NUG2MlUyKG6P	Mn22V2FPT0WU
NB12	NF7Ed4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfBWnJKUUN3ME21NlgvPDJibl2=	NXHtXlJLW0GQR1XS
SW756	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjyZVlJUUN3ME21OVQvQTZibl2=	M1uxT3NCVkeHUh?=
HCC1187	M2fTSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTvZYxKSzVyPUW3OU45OyCwTR?=	M4[4XnNCVkeHUh?=
NCI-H2342	M{XKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\jTWM2OD13OUCuN\|khdk1?	NF\ONotUSU6JRWK=
NCI-H2291	Ml3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnrVHNKSzVyPUW5PE4{OSCwTR?=	MkjwV2FPT0WU
OVCAR-3	Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHL4[olKSzVyPUW5PE46PiCwTR?=	MnvCV2FPT0WU
MHH-NB-11	NEPBdmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzHV2pKUUN3ME22NlkvODFibl2=	M17hcHNCVkeHUh?=
SAS	M1vNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFrVO2FKSzVyPU[1Nk43PyCwTR?=	NVzGNWFvW0GQR1XS
COLO-824	MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoDqTWM2OD14OEmuN\|chdk1?	MYrTRW5ITVJ?
HCC1395	NGn1dZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTZ7OD61JI5O	NXPUSlVzW0GQR1XS
COLO-668	Ml\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW0ZnlCUUN3ME23NFYvOSCwTR?=	Mo\QV2FPT0WU
NCI-H226	MnjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2r2cGlEPTB;N{C3Mlghdk1?	NIT3d4pUSU6JRWK=
NB17	MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVnnNHFbUUN3ME23NlEvPzVibl2=	MXTTRW5ITVJ?
SW1463	M{\Yc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTd\|OT6xPUBvVQ>?	NVLxSoloW0GQR1XS
TGW	NX7iOGZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XmfWlEPTB;N{[wMlE2KG6P	M1jtcnNCVkeHUh?=
NCI-H526	NHPnT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPKTWM2OD16MkOuOVMhdk1?	MlvYV2FPT0WU
COR-L88	NET0U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjCTWM2OD16NEiuNVIhdk1?	NIDaeYJUSU6JRWK=
NCI-H441	NXjIbW5WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1K4VmlEPTB;OEm1MlIzKG6P	MWLTRW5ITVJ?
NCI-H630	M1j2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHJTWM2OD17MUKuPVYhdk1?	MlL2V2FPT0WU
Mo-T	NYXtXHE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\qOmlEPTB;OUS3Mlg5KG6P	NUHnU3BtW0GQR1XS
JAR	NVOyeXNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXXJR\|UxRTl3Nj6yOEBvVQ>?	MlvjV2FPT0WU
NCI-H1838	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHhSGVKSzVyPUGuNFI{QDhizszN	NYTJZXd{W0GQR1XS
DoTc2-4510	M{\FUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHSemFlUUN3ME2xMlA4Ozd4IN88US=>	MkDEV2FPT0WU
MKN28	M4XpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlPaTWM2OD1zLkC5NFI1KM7:TR?=	M{XNTXNCVkeHUh?=
HuP-T3	NFjoPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFr5OXJKSzVyPUGuNVE6ODVizszN	NHHrc\|hUSU6JRWK=
TE-9	NV[ycYszT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorkTWM2OD1zLkGyPVc{KM7:TR?=	M4fXVnNCVkeHUh?=
NY	MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPVXJpKSzVyPUGuNVY4QTJizszN	NFTIT3hUSU6JRWK=
HT55	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3ybXFKSzVyPUGuN\|E{PDRizszN	MoLOV2FPT0WU
SW837	M{jQUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1W3U2lEPTB;MT6zNlk4QCEQvF2=	M2XoVnNCVkeHUh?=
NCI-H2029	NHzDeIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTFwNEG3PVEh\|ryP	MYLTRW5ITVJ?
IST-SL1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jpT2lEPTB;MT60OFI1KM7:TR?=	MVLTRW5ITVJ?
COLO-741	M3LU[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MY\JR\|UxRTFwNEm3O\|Eh\|ryP	NHf1RpRUSU6JRWK=
LU-65	MlTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFS3fnhKSzVyPUGuOlIzPDlizszN	M4XadHNCVkeHUh?=
NCI-H1304	Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PuPGlEPTB;MT62OVQ6QCEQvF2=	MmnWV2FPT0WU
KARPAS-299	NVf5NGtuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwN{m0O\|kh\|ryP	MWLTRW5ITVJ?
NCI-H358	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUe3NnBtUUN3ME2xMlk2PTB\|IN88US=>	M2H2UnNCVkeHUh?=
OAW-28	MoP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrETWM2OD1{LkC2PVE6KM7:TR?=	M3;ofnNCVkeHUh?=
C8166	NHLKSXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInjXWJKSzVyPUKuOlM{QTJizszN	M4D5fHNCVkeHUh?=
COLO-678	NWLydGttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjIOWJKSzVyPUKuPFM4PjhizszN	NEXkfnBUSU6JRWK=
SK-N-DZ	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTJwOE[zPFEh\|ryP	MYrTRW5ITVJ?
NCI-H82	NInJWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGTTcIVKSzVyPUKuPVA{PjlizszN	MWTTRW5ITVJ?
JVM-2	M4XHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NELtZ5ZKSzVyPUOuNFMyQDhizszN	MmTJV2FPT0WU
SW1116	NVLnWnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUD2Z\|RNUUN3ME2zMlA2PDFzIN88US=>	NX\4fnpxW0GQR1XS
MDA-MB-453	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofsTWM2OD1\|LkGwOFM6KM7:TR?=	NWjpfIYyW0GQR1XS
Calu-6	NVvU[5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfYTWM2OD1\|LkG5PVch\|ryP	M{\5cXNCVkeHUh?=
SHP-77	NH34UGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fX[WlEPTB;Mz61Nlgh\|ryP	MmLiV2FPT0WU
Capan-2	M1rmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYrEXWxlUUN3ME20MlMzPThzIN88US=>	M1;tWHNCVkeHUh?=
SW948	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjxTWM2OD12Lke0O\|c6KM7:TR?=	M{Dnc3NCVkeHUh?=
HDLM-2	NV3lRXAzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnGwTWM2OD13LkC3O\|I2KM7:TR?=	MWjTRW5ITVJ?
LAN-6	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPkNlFKSzVyPU[uNlE1QTVizszN	MXnTRW5ITVJ?
LU-135	NX\VeoVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{n2N2lEPTB;Nj60N\|A4PyEQvF2=	Ml7lV2FPT0WU
T84	NE[wcHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTMNJdvUUN3ME22Mlk5PjRizszN	M1v4WXNCVkeHUh?=
CAPAN-1	M1\nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\td5QxUUN3ME23MlYzOjN\|IN88US=>	NV;4W203W0GQR1XS
SW1417	MoPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{C3[WlEPTB;Nz65NVc{OSEQvF2=	MkC3V2FPT0WU
BALL-1	NVfT[XE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVvJR\|UxRThwNUC0NFkh\|ryP	M{PWbnNCVkeHUh?=
HT-29	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2TP[mlEPTB;OT6wO\|U6QSEQvF2=	NIDiNGtUSU6JRWK=
C3A	M33XZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jxPWlEPTB;OT64PFM6PCEQvF2=	NV;tU2lzW0GQR1XS
NCI-H1993	M3m3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFyLkWwPFEh\|ryP	MlL5V2FPT0WU
SK-MEL-1	M4nVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nsdGlEPTB;MUGuOlI5QSEQvF2=	NETMTHlUSU6JRWK=
DU-145	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV75PVNqUUN3ME2xOE42ODV{IN88US=>	MlK2V2FPT0WU
KP-N-YN	MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmPLTWM2OD1zND61NVA{KM7:TR?=	NFXCd5NUSU6JRWK=
CCRF-CEM	M{\ycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;mVnJKSzVyPUG0Mlc5ODlizszN	Ml24V2FPT0WU
ZR-75-30	M33NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonxTWM2OD1zNj6zN\|A{KM7:TR?=	MXHTRW5ITVJ?
A673	MkLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTJyLkW1NFch\|ryP	M1y1d3NCVkeHUh?=
K-562	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{PiWmlEPTB;MkiuOFE5OyEQvF2=	NH7EUGZUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Myc / Vinculin / pT58 Myc; PubMed: 25934076 Cancer Discov Immunoblots documenting MYC and pT58 MYC stability. SW480 cells were treated with 200nM BEZ235 or solvent control for 24h and cycloheximide (50µg/ml) and harvested at the indicated time points. Vinculin was used as loading control. Exposures of MYC and pT58 MYC blots were adjusted to equalize exposure at 0 min (n=3; unless otherwise indicated, n indicates the number of independent biological repeat experiments in the following legends). pAkt / Akt / Skp2 / AR / pS6 / p27; PubMed: 24347472 Prostate BEZ235 decreases Skp2 and increases AR protein expression inC4-2B cells. Cells were treated with BEZ235 at various doses. Cell lysates were subjected to Westernblot analysis with indicated antibodies. p-S6K / S6K / p-Akt / Akt / p-ABL / BCR-ABL; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the phosphorylation levels of S6K, Akt (Ser473), and BCR–ABL in CML cells. Results of Western blot. Bcl-2 / Caspase-3 / Cleaved caspase-3 ; PubMed: 28435223 Drug Des Devel Ther K562 (A1) and KBM7R (A2) cells were treated with BEZ235 for 24 h; total protein lysates were immunoblotted with antibodies for Bcl-2, caspase-3, and cleaved caspase-3. Cyclin D1 / Cyclin D2 ; PubMed: 28435223 Drug Des Devel Ther Dose-dependent inhibition effect of BEZ235 on the expression levels of cyclin D1 and cyclin D2 in K562 and KBM7R cells. Western blot results of K562 (A1) and KBM7R (A2) cells. mTOR / p-mTOR / p70S6K / p-p70S6K ; PubMed: 29581778 J Cancer Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. p-EGFR-Tyr1068 / EGFR / p-HER2-Tyr1221 / p-HER2-Tyr1222 / HER2 / p-HER3-Tyr1289; PubMed: 21278786 Oncogene Immunoblots of protein lysates from BT474 and MCF7-HER2 cells treated with either BEZ235 alone (0–500 n) or the combination of BEZ235 (0–500 n) and the tyrosine kinase inhibitor lapatinib (LAP, 500 n) for 24 h.	25934076 24347472 28435223 29581778 21278786
Immunofluorescence	SP1;

研究领域